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Lutein is a xanthophyll synthesized by plants. In biological systems, lutein has 
antioxidant and anti-inflammatory properties, which could protect against chronic 
diseases. Despite its potential as a bioactive food component, lutein intake is low 
among Americans. In addition, lutein has low bioavailability, making it difficult to 
achieve biological effects. One approach to overcome these challenges is the 
use of nanotechnology. 
This project evaluated the effects of a lutein nanoemulsion (NANO) on hepatic 
steatosis and systemic inflammation in guinea pigs. Our hypothesis was that 
NANO lutein would be more bioavailable and, therefore, more effective than 
powdered lutein (PL) in protecting against cholesterol-induced damage.  
The nanoemulsion had an average particle size of 165.4 nm, a PDI of 0.195 and 
a ζ-potential of -40.5 mV, indicating a stable and monodisperse preparation.  
Twenty-four male Hartley guinea pigs were allocated to one of three groups 
(n=8/group): control (0 mg lutein), PL (0.02% lutein) or NANO (0.02% 
Ana Gabriela Murillo Solis, PhD - University of Connecticut, 2016 
 
nanoemulsified lutein). All diets contained 0.25% cholesterol. After 6 wk, plasma, 
livers, and adipose tissue were collected for analysis.  During the study, animals 
in both treatment groups consumed an average of 3.5 mg lutein/day. The NANO 
group had higher plasma and liver lutein concentrations compared to PL, 
indicating that lutein given in a nanoemulsion is more bioavailable.  
 
In the liver, the NANO group had lower steatosis scores, accumulation of total 
and esterified cholesterol, and plasma ALT when compared to PL and control. 
Hepatic oxidized LDL was lower in both PL and NANO compared to control. 
Further, mRNA expression of DGAT2 was lower in the NANO group when 
compared to control or PL.  
 
In plasma, the NANO group had higher LDL and HDL cholesterol concentrations 
and VLDL, LDL and HDL particle number compared to PL and control. 
Furthermore, the NANO group had 15% higher free cholesterol concentrations in 
adipose tissue, resulting in higher concentrations of inflammatory markers 
compared to the other treatments.  
 
Overall, this nanoemulsion increased the bioavailability of lutein and protected 
the liver while plasma lipoproteins and systemic inflammation were increased, 
suggesting that the metabolic effects of this particular nanoemulsion are not 
protective to all tissues in guinea pigs.   
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Chapter 1 
Introduction 
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One of the main concerns related to the western diet is the increased intake of certain 
nutrients such as saturated and trans fats, simple carbohydrates, and sodium, among 
others, and the negative effects that these have on human metabolism. In the United 
States, chronic diseases attributable to the western diet represent a serious threat to 
public health [1]. The increasing rates of obesity, type 2 diabetes (T2DM), 
atherosclerosis, non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and 
cardiovascular disease (CVD) are strongly associated with non-healthy dietary patterns 
and low physical activity [2,3].  
 
In contrast, epidemiological studies show a link between a high intake of plant-derived 
foods such as wine, fruits, nuts, vegetables, grains, legumes, and spices and a variety 
of health benefits such as lower incidence of metabolic syndrome (MetS), dyslipidemia, 
T2DM, CVD and certain types of cancer [4–7]. One of the reasons that consumption of 
these foods is associated with so many health benefits is the presence of non-nutrient 
secondary metabolites, also known as phytochemicals or bioactive components. These 
phytochemicals have been shown to exert a wide range of biological activities in vitro 
and in vivo [5]. Most phytochemicals have antioxidant capacity and since oxidative 
stress is thought to be involved in the etiology of many chronic diseases affecting the 
global population, these compounds are of great interest in health and nutrition research 
[8,9].  
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Among these phytochemicals, carotenoids, a family of pigmented and lipophilic 
compounds synthesized only by plants and some microorganisms, have received 
special attention [10–13]. For example, many studies have been conducted with 
lycopene and its relationship to prostate cancer [14], or with lutein/zeaxanthin and the 
prevention of age related macular degeneration (AMD) and the promotion of eye health 
[15–17]. Lutein is an oxygenated carotenoid that is particularly abundant in green leafy 
vegetables such as kale and spinach and yellow foods such as corn and egg yolks. In 
addition to being important for the maintenance of eye health, lutein may also enhance 
immune function, protect against cancer, CVD, and oxidative stress-related diseases 
[18–20]. 
Given the potential of bioactive components to prevent or modulate the high prevalence 
of chronic diseases, there is a large market for nutraceuticals which are defined as food-
derived phytochemicals in pharmaceutical forms (pills, powders, capsules, vials etc.) [5]. 
Lutein is no exception, and this carotenoid can be found as an individual supplement or 
as a component of multivitamins, with the claim that its regular consumption can 
promote health [19].  
However, as with other carotenoids and lipophilic phytochemicals, lutein has a very 
inconsistent and variable bioavailability [19,21,22]. This is because bioavailability of 
lutein depends on several factors including the food matrix, the source of lutein, the 
presence of other meal components such as fiber, fat or other carotenoids and the 
health status and genetics of the host [23–25]. Different approaches to enhance the 
absorption of lutein from foods or supplements are being studied [26,27]. One of these 
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approaches is nano-technology, which is the use of materials on the nanometer (10−9 
m) scale designed to be transported in encapsulated carriers with improved water 
solubility, thermal stability, oral bioavailability and physiological performance [28]. This 
methodology has been successfully used with drugs, vaccines, and other vitamins and 
nutrients [29–32]. 
However, it is important to understand the differences in bioavailability, metabolism, 
tissue distribution, and even possible toxicity of these nanoparticle-delivered 
nutraceuticals [5]. For this reason, we developed a study that would characterize and 
evaluate the effects of feeding a nanoemulsion of lutein to cholesterol-challenged 
guinea pigs. 
The main objective of this project is to develop and test a nanoemulsion of lutein in the 
protection of cholesterol-induced hepatic steatosis and systemic inflammation in guinea 
pigs.  Our central hypothesis is that the nanoemulsion, by enhancing the bioavailability 
of lutein, will be more efficient than regular lutein in reversing the hepatic and systemic 
damage caused by the hypercholesterolemic diet in a guinea pig model.  
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2.1. Cholesterol  
 
2.1.1 Cholesterol definition and cellular importance 
 
Cholesterol is a non-energetic, 27 carbon, steroidal, unsaturated lipid that plays a vital 
role in cell biology [1,2]. It is an important component of cell membranes in higher 
eukaryotes, by regulating their fluidity, stability and permeability [3].  Cholesterol is also 
the precursor of vital biomolecules such as corticosteroids, bile acids, vitamin D and 
sexual hormones [1,4]. In mammals, most organs satisfy their needs for cholesterol via 
endogenous de novo biosynthesis from acetyl-CoA [1,5], however, 30% of the 
cholesterol pool is obtained from the diet (exogenous cholesterol), which many cells can 
internalize from lipoproteins [1,3,5].   
 
In the cell, cholesterol can be found in two main forms: free or esterified with a ratio of 
approximately 3:7 [1]. The molecule is free when the hydroxyl group in carbon 3 can 
form hydrogen bonds or form an ester with a carboxylic acid, which means that the 
compound has some polarity; esterified is when the hydroxyl group has a fatty acid 
attached by an ester bond which makes the molecule highly hydrophobic [6].  
 	
2.1.1 Endogenous cholesterol synthesis  	
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All nucleated cells can synthesize cholesterol through the mevalonate pathway. This 
process requires 20 enzymes to assemble 30 carbons from acetyl-Co A into a 27-
carbon planar structure with four rings. The rate-limiting enzyme of this pathway is 
hydroxymethylglutaryl CoA reductase (HMGR), which catalyzes the synthesis of 
mevalonate from acetyl-CoA [3]. HMGR is tightly regulated through transcription, 
translation, post-translational modification and degradation [7]. This enzyme has been 
widely studied and it is the target for statins, a commonly used cholesterol lowering drug 
[8].  
 
2.1.3 Dietary cholesterol absorption 	
In western societies, cholesterol intake is around 200–600 mg/day [9] from which 40-
80% is absorbed [4]. Since this molecule is poorly soluble in water, it has to be 
emulsified upon intake with bile salts, cholesterol-derived amphiphilic molecules 
synthesized in the liver, which in contrast with their precursor, are very soluble given 
their capacity to self-associate [2,10]. This emulsification process is similar to that used 
for other fat components of the diet, including phospholipids and triglycerides [9]. About 
10–15% of dietary cholesterol is esterified, and before absorption these esters are 
cleaved by a pancreatic enzyme, carboxyl ester lipase, however, most of the dietary 
cholesterol does not require pancreatic hydrolysis [9,11]. 
Although it is generally accepted that cholesterol is absorbed via passive diffusion by 
the enterocytes, studies have found that intestinal uptake of cholesterol occurs by 
protein-mediated intestinal uptake [9,10]. 
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The main cholesterol transporter located in the apical membrane of enterocytes is 
identified as Niemann-Pick C1-like 1 (NPC1L1) protein [3,12,13]. Studies have also 
shown that there is another facilitated transport mechanism that sends intracellular 
sterols back into the small intestine for fecal excretion. These efflux transporters are the 
ATP-binding cassette (ABC) proteins ABCG5 and ABCG8 [12]. Once inside the 
intestinal cell, acyl-CoA:cholesterol acyltransferase (ACAT) catalyzes the esterfication 
of cholesterol; an important step prior to the packaging of cholesterol into nascent 
chylomicrons (CM) [3,4,12]. 
 
2.1.4 Cholesterol metabolism 
 
As with other lipophilic compounds, cholesterol cannot be transported into the 
bloodstream without lipoproteins. These are amphipathic structures with a polar surface 
composed by a layer of phospholipids, free cholesterol and apo-proteins; and a non-
polar core made up by triglycerides, cholesteryl esters (CE) and fat soluble vitamins 
[12]. When dietary cholesterol is transported from the intestine to inside the body, it is 
mainly carried by CM, a triglyceride rich lipoprotein characterized by the presence of 
ApoB-48 [14]. CM travel via the lymphatic system and reach the bloodstream at the 
level of the subclavian vein via the thoracic duct [15]. In the lymph and blood, CMs 
acquire other apo proteins such as apoCI, apoCII, apoCIII and apoE. ApoCII activates 
the endothelial cell-associated lipoprotein lipase (LPL), which hydrolyzes the 
triglycerides from the core of CMs and the resulting free fatty acids (FFA) are 
transported to the extra hepatic tissues for energetic needs or storage. LPL mediated 
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triglyceride hydrolysis decreases the size and increases the density of the particles, 
leaving CM ‘remnant’ particles, which are enriched in CE. CM remnants are taken up by 
the liver via the hepatic LDL receptor (LDL-R) and LDLR-related protein-1 (LRP1) 
through the interaction with ApoE. 12-14 hours after a meal, all CMs are cleared from 
circulation [12,16,17].  
 
The liver synthesizes and secretes another class of triglyceride-rich lipoprotein, known 
as very low-density lipoprotein (VLDL). VLDL contains ApoB100, apoE, apoCII and 
apoCIII and is also packed up with endogenous cholesterol, lipid soluble vitamins and 
carotenoids [18].  VLDL is also a target for LPL, which hydrolyzes its triglyceride 
content, leaving a much denser, cholesterol-rich remnant particle and ultimately low-
density lipoproteins (LDLs) [17,19].  
 
High-density lipoproteins (HDL) play a crucial role in cholesterol metabolism, because 
they orchestrate reverse cholesterol transport (RCT), the transport of cholesterol from 
peripheral tissues to the liver [12]. An important feature of HDL is its maturation 
process. ApoA-I, expressed and secreted predominantly by the liver (70%) and small 
intestine (30%) acquires small amounts of phospholipids, creating very small HDL 
particles. These particles bind to ABCA1 in the liver, intestine, or macrophages, 
acquiring free cholesterol (FC) and increasing their lipid content, thus becoming discoid-
shaped larger HDL particles or small HDL.  
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Lecithin-cholesterol acyl-transferase (LCAT) catalyzes the transfer of an acyl group from 
lecithin to FC and generates hydrophobic CE, which readily move to the core of HDL 
particles, producing a steady gradient of free cholesterol. This process promotes the 
efflux of cholesterol from cells like vascular macrophages and other peripheral tissues, 
thus leading to the formation of more spherical mature particles or medium HDL. Mature 
HDL bind with ABCG1 and scavenger receptor B1 (SR-BI), which are responsible for 
additional cholesterol efflux to mature HDL particles, further increasing the size and CE 
content [20–22]. 
 
Further, HDL remodeling by plasma and cell surface enzymes is mediated by ABCG1, 
hepatic lipase, endothelial lipase, cholesterol ester transfer protein (CETP), and 
phospholipid transfer protein. In humans, HDL-cholesterol (HDL-C) can be returned to 
the liver via two pathways: direct hepatic uptake by SR-B1; or through CETP exchange 
of CE for TG in apoB-containing lipoproteins (CM and VLDL), followed by hepatic 
uptake of these apoB-containing particles by the LDL receptor [23].  
 
Multiple epidemiological studies have shown a strong association between high 
concentrations of HDL-C and reduced risk of CVD, and low concentrations of HDL-C 
with increased CVD. Therefore HDL-C is referred commonly as the “good” cholesterol 
[23]. However, besides promoting RCT, HDL particles also enhance antioxidant, anti-
inflammatory, vasodilatory, and antithrombotic activities [24]. 
 
2.1.5 Cholesterol challenge 
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Since cholesterol plays an important role in normal metabolism, the cholesterol pool is 
tightly regulated, and either a major decrease or increase of this molecule is a risk factor 
for disease [1].  
 
Numerous studies have suggested that dietary cholesterol increases plasma TC 
concentrations in humans and it has been shown that increases in LDL-C without a 
consequent increase in HDL-C is a major risk factor for atherosclerosis and CVD 
[25,26]. However, experimental data indicate that individuals vary considerably with 
respect to their response to dietary cholesterol and that dietary cholesterol does not 
change the LDL: HDL ratio [27]. Mean intakes in the U.S. are around 224 mg and 333 
mg cholesterol per day, which should not represent an increased risk for CVD [26].  
 
Cholesterol challenges, however, with dosages far above the usual intake, have been 
shown to alter homeostasis and develop metabolic disorders such as dyslipidemia, 
endothelial dysfunction, hepatic steatosis, CVD and systemic inflammation [1,28–30]. In 
guinea pigs, our laboratory has shown that a challenge of 0.25% of dietary cholesterol 
for six weeks results in hypercholesterolemia when compared to a control group  (284 
vs 48 mg/dL; p=0.0001) and elevated plasma activity of liver enzymes, Alanine amino 
transferase (ALT) and aspartate amino transferase (AST), which are biochemical 
indicators of hepatic damage. Moreover, the cholesterol challenge also caused hepatic 
steatosis, denoted by increased accumulation of TG along with total, free, and esterified 
cholesterol. In this time period, that amount of cholesterol was also capable of causing 
hepatic inflammation and injury seen as single cell necrosis in liver tissue [31]. 
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2.2 Oxidative stress and Inflammation 
 
2.2.1 Oxidative stress 
A free radical is any chemical species that contains unpaired electrons. This unpaired 
electron usually produces a highly reactive free radical [32]. In biological systems, free 
radicals are formed as by-products of normal cellular function such as oxidative 
phosphorylation in the mitochondria [33,34]. These by-products are generally reactive 
oxygen species (ROS) as well as reactive nitrogen species [35].   
 
Free radicals can cause damage to cellular proteins, membrane lipids and nucleic 
acids, and eventually cell death; however, the human body has several mechanisms to 
counteract this damage by the use of antioxidants, which are either naturally produced 
in situ (endogenous), or externally supplied through foods and/or supplements 
(exogenous) [35,36]. Based on their activity, antioxidants can be categorized as 
enzymatic when they break down and remove free radicals through enzymatic 
reactions. Examples of these antioxidants are superoxide dismutase, catalase  and 
glutathione peroxidase. Non-enzymatic antioxidants work by interrupting free radical 
chain reactions, examples of the non-enzymatic antioxidants are vitamin C, vitamin E, 
polyphenols, carotenoids and glutathione [37]. 
 
When the production of pro-oxidant free radicals is higher than the organism's capacity 
to counteract their action with antioxidant systems, the organism faces oxidative stress 
[28,38,39]. It is hypothesized that oxidative stress plays a major role in the development 
and progression of chronic and degenerative diseases such as cancer, autoimmune 
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disorders, cataract, cardiovascular and neurodegenerative diseases, among others [35].  
2.2.3 Chronic inflammation 
Inflammation, under normal conditions, is an essential component of the innate immune 
response to pathogens and a protective mechanism against tissue damage [40]. 
However, the persistence of inflammation over a prolonged period increases the risk of 
cellular and tissue injury. This chronic inflammation is characterized by the up-regulation 
of systemic indicators such as leucocyte count, and serum and plasma concentrations 
of acute-phase proteins, pro-inflammatory cytokines, chemokines, soluble adhesion 
molecules and prothrombotic mediators [41].   
 
Obesity, insulin resistance and T2DM are closely associated with low grade chronic 
inflammation, which is further considered the underlying mechanism for several 
metabolic complications such as MetS, atherosclerosis and certain types of cancer [42–
44].  
 
In obesity, the adipose tissue mediates many of these inflammatory responses [45]. The 
expansion of adipose tissue mass, the distinctive feature of obesity, causes a series of 
alterations which induce the secretion of a number of inflammatory mediators including 
Tumor Necrosis Factor-alpha (TNFα), interleukin (IL) -1β, IL-6, monocyte 
chemoattractant protein 1 (MCP-1). This production of inflammatory adipokines has 
been implicated in the development of insulin resistance and MetS [46]. 
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Cholesterol metabolism also plays a role in inflammation. There is abundant evidence 
that the interaction of LDL with macrophages in atherosclerotic plaques leads to an 
increase in inflammatory gene expression [47].  Animal studies have shown that excess 
dietary cholesterol leads to an increase in macrophage accumulation in the adipose 
tissue, increasing insulin resistance and chronic systemic inflammation [48]. 
Accumulation of cholesterol in the adipocytes has been shown to be cytotoxic, inducing 
apoptosis and the recruitment of pro-inflammatory cells and aggravating the state of 
systemic inflammation [49,50] 
 
2.2.4 Link between oxidative stress and inflammation 
As previously stated, oxidative stress and inflammation are both linked to many chronic 
diseases, and a very important feature of these processes is that oxidative stress and 
inflammation are known to induce each other [40]. For example, ROS can stimulate the 
production of oxidized LDL (OxLDL), which is not recognized by the LDL receptor but 
can be taken up by macrophages. OxLDL induces the activation of peroxisome 
proliferator-activated receptor gamma (PPARγ), and influences the expression of 
downstream genes leading to foam cell formation, inflammation and atherosclerosis 
[51]. Some radicals like •O2- and H2O2 can also stimulate stress-related signaling 
mechanisms such as nuclear factor kB (NF-κB) and p38- (MAPK) leading to 
inflammatory responses [38]. Similarly, during inflammation, cells of the immune system 
such as macrophages and leucocytes are recruited to the site of damage. This results in 
a “respiratory burst,” an overproduction of ROS, and consequently oxidative stress [42]. 
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Given the relationship of oxidative stress and inflammation, the use of antioxidants from 
natural sources has become increasingly important as therapeutic agents against 
oxidative stress and inflammation-related diseases [39,52–54]. While it is commonly 
believed that antioxidant bioactive components, given their capacity to scavenge ROS, 
have an indirect impact on inflammation, some authors suggest that these antioxidants 
are also capable of interacting directly with inflammatory pathways [42,55].  	
2.3 Non alcoholic fatty liver disease (NAFLD) 
 
2.3.1 Definition 
 
Nonalcoholic fatty liver disease (NAFLD) is the broad spectrum of hepatic diseases, 
which vary from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), 
which can progress to fibrosis, cirrhosis and hepatocellular carcinoma. The 
pathogenesis of NAFLD excludes excessive alcohol intake (less than 20 g of alcohol 
per day), use of steatogenic medication or hereditary disorders [56–59].  
 
NAFL is defined as the presence of hepatic steatosis without ballooning degeneration 
and inflammation in the hepatocytes. This steatosis is product of the abnormal TG 
accumulation in hepatocytes as a result of an imbalance between the uptake of fat and 
its oxidation and/or export [58,60].  
 
NASH is a necro-inflammatory disease, defined as the presence of diffuse fatty 
infiltration in the liver and characterized by ballooning and inflammation in the 
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hepatocytes with or without fibrosis. NAFL is mostly benign and risk of progression to 
cirrhosis and liver failure is minimal, whereas NASH can lead to further life threatening 
complications [56,59].  
 
2.3.2 Epidemiology and importance 
 
NAFLD is the most common cause of abnormal liver function among adults in the 
United States [61]. The prevalence of this disease ranges between 25-45% increasing 
in parallel with other chronic problems such as obesity. Current estimates suggest that 
68% of US adults are overweight or obese; which means that 75 million and 100 million 
adult individuals in the United States likely have NAFLD [62].  The prevalence of NASH 
is less common, affecting an estimated 2–3% of the general population and up to 37% 
of the morbidly obese [63].  
 
An alarming fact is that even though NAFLD is commonly referred as an exclusively 
adult disease, the rising prevalence of obesity and T2DM in children and adolescents 
over the last two decades has made NAFLD emerge as the leading cause of chronic 
liver disease in this segment of the population [62,64]. Moreover, it is predicted that by 
2030, NALFD will be the most frequent indication for liver transplantation [65]. There is 
now growing evidence that NAFLD is not only confined to hepatic-related morbidity and 
mortality, but is a multisystem disease, affecting several extra-hepatic organs [65] 
 
2.3.3 Pathogenesis  
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Insulin resistance (IR) is the most consistent underlying pathogenic factor for hepatic 
steatosis. IR increases lipolysis of peripheral fat through increased hormone-sensitive 
lipase activity with mobilization and uptake of free fatty acids by the liver [58,66]. 
However, most experts agree that fat accumulation in the hepatocytes is not enough to 
induce progressive liver damage, but it is the first step of a series of molecular and 
physiologic alterations that occur in the progression of NAFLD [64,66]. Triglyceride 
accumulation in hepatocytes increases the vulnerability of the liver to other insults 
through effects of cytokines or oxidative stress [67] since the circulating FFAs are not 
only substrate for TG synthesis but may also be directly cytotoxic [68]. 
 
 Day et al. [69] proposed a “two-hit” hypothesis which states that after lipid accumulation 
in the liver (first hit) additional cofactors (hit 2)  such as  oxidative stress, lipotoxicity, 
adipocytokines, alterations in mitochondrial permeability and stellate cell activation, 
among others, are needed to induce persistent liver injury leading to NASH [69]. 
 
As stated previously, cholesterol feeding could induce dyslipidemia and insulin 
resistance. In animal models an excess of dietary cholesterol also appears to be an 
important risk factor for hepatic steatosis and progression to steatohepatitis. [29,67,70] 
 
2.3.4 Dietary interventions 	
The increasing prevalence of NAFLD and comorbidities is likely caused by malnutrition 
and sedentary lifestyles characteristic of the modern world [60]. As unhealthy dietary 
patterns can lead to the development of this disease, several studies have 
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demonstrated a positive impact of dietary interventions in treating obesity, IR, and 
NAFLD [71]. 
 
Studies have shown a positive correlation between monounsaturated fatty acids and 
polyunsaturated fatty acids, specifically n-3, and decreased liver fat content, suggesting 
a protective role of these fatty acids in the progression of NAFLD [72]. In guinea pigs, a 
carbohydrate restriction diet showed to attenuate hepatic cholesterol accumulation 
induced by a cholesterol challenge [73]. These results have been also seen in humans, 
as low-carbohydrate diets has been shown to lead to lower serum ALT and hepatic 
steatosis [64]. 
 
Standard dietary interventions for NAFLD include macronutrient intake modifications 
such as carbohydrate and fat restriction; in addition, emerging dietary therapies for 
NAFLD include the use of antioxidants such as vitamins C, E and polyphenols, betaine, 
anthocyanins, curcumin and resveratrol [63,74]. Among these antioxidants, carotenoids 
have received special attention. In the National Health and Nutrition Examination 
Survey (NHANES) III, higher levels of serum carotenoids were associated with lower 
presence of apparent liver injury, as indicated by liver enzymes [75] 
2.4 Carotenoids  
 
2.4.1 Definition 
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Carotenoids are a class of isoprenoid compounds consisting of 40 carbon atoms known 
as tetraterpenoids [76]. These lipid soluble phytochemicals are mainly synthesized by 
plants and photosynthetic bacteria as pigments and they constitute part of the 
antioxidant machinery [77,78]. Carotenoids protect cellular structures against oxidative 
damage by scavenging singlet molecular oxygen and peroxyl radicals usually caused by 
light and normal plant metabolism [78–81].   There are more than 700 naturally-
occurring carotenoids identified, but only around 50 are present in the human diet and 
among these, only 6 (beta-carotene, beta-cryptoxanthin, alpha-carotene, lycopene, 
lutein, and zeaxanthin) represent more than 95% of the carotenoids found in human 
blood [82]. 
 
Structurally, carotenoids can be classified into oxygen-lacking carotenes and oxygen-
containing xanthophylls. The latter contain hydroxyl groups, which provide an 
amphipathic character, allowing xanthophylls to be inserted into the lipid bilayer of cell 
membranes and the outer monolayer of lipoproteins [83–85]. In recent years, special 
attention has been focused on biological activities of dietary xanthophylls such as lutein, 
zeaxanthin, β-cryptoxanthin, capsanthin, astaxanthin, and fucoxanthin [86]. 
 
Functionally, carotenoids can be categorized into pro and non pro vitamin A. Pro vitamin 
A carotenoids can be metabolized into retinal and retinol and therefore contribute to 
general growth, maintenance of visual function, regulation of differentiation of epithelial 
tissues, and embryonic development [87]. Examples of provitamin A carotenoids include 
beta-carotene, alpha-carotene and beta-cryptoxantin [88]. Conversely, non-pro vitamin 
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A carotenoids are those that do not yield vitamin A. Despite not having potential vitamin 
A function, non provitamin A carotenoids have been studied and associated with a 
variety of health beneficial effects [76,89]. This group includes lycopene, lutein, 
zeaxanthin and astaxanthin, among others [90,91].  
 
Despite the fact that they are synthetized by animals and they are classified as organic 
compounds, carotenoids do not meet all the criteria for being considered vitamins and 
there is no daily recommended intake for them; however, lower serum concentrations of 
carotenoids have been positively associated with increased risk of CVD, T2DM, AMD, 
certain types of cancer and other chronic diseases [92–96]. Dietary sources of 
carotenoids include orange, red, and yellow fruits and green leafy vegetables, as well as 
egg yolk and some kinds of fish and crustaceans [82]. In most countries, however, 80–
90% of human carotenoid intake comes from fruits and vegetables [82,97] .  
 
2.4.2 Bioavailability  	
A very important aspect to consider when evaluating the effect of carotenoids in 
humans is the bioavailability of these compounds [86]. Bioavailability refers to the 
fraction of the ingested food component that is available for utilization or storage in 
normal physiological conditions [98]. It is futile to study in detail the health effects of 
dietary bioactive compounds if their bioavailability is not also fully understood [99]. For a 
bioactive to be bioavailable, it needs to be released from the food matrix after ingestion, 
be absorbed in the gastrointestinal tract, and be transported to the target tissue to exert 
a biological effect [99,100].  
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In the case of carotenoids, there are many factors that influence their bioavailability, 
which are commonly summarized by the mnemonic SLAMENGHI, grouped by De Pee 
& West in 1996 [101–103]. SLAMENGHI stands for 
a. Species of carotenoids: This refers to the configuration of the carotenoid molecule. 
In plants, carotenoids are usually all-trans isomer. Cis isomers, however, can be 
formed during food processing and are more polar and more soluble in oil than trans 
isomers [101,104]. Probably the most relevant example of how this affects 
bioavailability is the case of lycopene, the most abundant carotenoid present in 
tomatoes [105]. When lycopene uptake from processed and unprocessed tomato 
juice was compared in humans, the cis isomer was better absorbed than the all-
trans form [106].  
b. Molecular Linkage: In plants, xanthophylls are often esterified with fatty acids 
[76,107]. For example, lutein can be found as a lutein palmitate diester or 
monoester in some fruits like peaches and oranges [84]. Carotenoid esters cannot 
be absorbed in the intestine, however, since no esterified xanthophylls are found in 
plasma after ingestion, it its thought that these can be de-esterified by brush border 
enzymes prior to absorption [76,104,108]. These enzymes are esterases and 
lipases that are stimulated by bile acids and therefore, as long as there is enough 
fat present in the meal, molecular linkage does not affect bioavailability to a great 
extent [84,109].  
c. Amount of carotenoids consumed in a meal: Because all carotenoids follow the 
same absorptive pathway, these may interact with each other during intestinal 
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absorption and metabolism [84,101,108]. In a study that assessed whether 
carotenoids compete for intestinal absorption Tyssandier et al., reported that adding 
a second carotenoid to a meal that provided a first carotenoid diminished the 
chylomicron content of the first one suggesting that there may be a competition for 
absorption [110]. This competition can be at the level of micellar incorporation, 
intestinal uptake, lymphatic transport or at more than one level [76,103]. 
d. Matrix in which the carotenoid is incorporated: One of the main components of a 
compound’s bioavailability is its bioaccessibility, which is the fraction of carotenoid 
ingested that is released to the gastrointestinal lumen and thereby available for 
absorption in the intestine [84,99]. For a carotenoid to be bioaccessible, it has to be 
released from its food matrix and be incorporated and dissolved into a hydrophobic 
domain (bulk lipid emulsion, or mixed micelles) before it can be potentially absorbed 
[103,104,111,112]. In general, carotenoids dissolved in oil are more bioavailable 
than carotenoids that come directly from their food source [82,101]. Within plants, 
carotenoids are typically found in chromoplasts and chloroplasts, where they are 
bound to complex proteins which would decrease their bioaccessibility [76,103].  
Protein binding can explain the low bioavailability of carotenoids from dark-green 
leafy vegetables [101]. Besides, carotenoids are hardly released from raw 
vegetables due to the solid structure of the cell walls. In this case, processing 
including heat treatment can accelerate the release of carotenoids by destroying 
these structures [86,98]. 
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e. Effectors of absorption and bioconversion: Many nutrients consumed together with 
carotenoids may affect carotenoid absorption, metabolism, transportation and/or 
bioconversion [101].  
 
Dietary fat 
In general, the presence of fat in the meal increases carotenoid solubilization, 
micellarization and secretion in chylomicrons and therefore, their bioavailability. Dietary 
fat also stimulates bile secretion and increases the quantity of carotenoids carried in 
micelles [76,103]. However, lipids do not influence all carotenoids to the same extent, 
being more important for highly lipophilic carotenes and esterified xanthophylls than for 
partially polar free xanthophylls [76,102]. Furthermore, the requirement for fat in the 
meal seems to be higher for unprocessed vegetables, than that for cooked meals [113]. 
       
Dietary Fiber 
One of the main effects of dietary fiber on lipid metabolism relies on its interaction 
with bile acids, resulting in a lower lipase activity and decreased absorption of fats and 
fat-soluble substances, such as dietary cholesterol and carotenoids [76,101,111]. The 
presence of dietary fiber in fruits and vegetables may be another explanation for the 
lower bioavailability of carotenoids from plant-derived foods [103,112]. 
f.  Nutrient and health status of the host: Some differences in absorption of 
carotenoids can be due to underlying nutritional problems with the host, for 
example, fat malabsorption can impair the uptake of lipid soluble nutrients, such as 
vitamins and carotenoids [84]. It has also been speculated that aging decreases the 
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absorption of nutrients because of age-related changes in gastrointestinal pH and 
digestive enzyme efficiency [76,114].   
g.  Genetic factors:	In human studies, there is an important inter-individual variability in 
blood and tissue concentrations of carotenoids. Some individuals display little or no 
change in plasma concentration of carotenoids after supplementation, whereas 
others show important changes [108,115] In addition to the variable intake of these 
compounds, these differences can be explained by variants in genes encoding for 
the proteins involved in carotenoid absorption and metabolism [116]. This variation 
suggests that, as is the case with dietary cholesterol, there are hyper- and hypo-
responders to carotenoids [25,115]. 
 
h. Host-related factors: Some of the differences observed in the serum response to 
ingestions of dietary carotenoids can be explained by differences in lifestyle and 
body composition of the host [101]. For example, a study by Gruber et al. found 
significant correlations between lower serum lutein and zeaxanthin and several 
factors such as smoking, heavy drinking, not being physically active, having higher 
percentage of fat mass, a higher waist-hip ratio, lower serum cholesterol, a higher 
white blood cell count, and high levels of C-reactive protein [117].  
i. Interactions: This term refers to the differences that can be observed when two or 
more of the factors mentioned before play a role together and have a synergistic 
effect over carotenoids bioavailability compared to the effects observed by each 
factor independently [101].  
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Given the many factors that determine carotenoids’ bioaccessibility, the amount of 
carotenoid bioavailable can vary from less than 10% to 50% of the amount consumed 
[118].  
 
Improving bioactive components bioavailability has become an important focus in 
nutritional sciences research. With an increased bioavailability, carotenoids bioefficacy 
can also be improved [99,119]. Many approaches have been taken to overcome the low 
bioavailability obstacle of phytochemicals. These include chemical modification of the 
molecules of interest, design of colloidal systems to encapsulate them and the use of 
nanosystems [99].  
 
2.4.3 Bioactivity 	
As mentioned before, epidemiological studies have suggested a positive link between 
higher consumption and tissue concentrations of carotenoids and lower risk of chronic 
disease [77,78]. The main mechanism by which carotenoids exert these beneficial 
effects is their antioxidant capacity [78,120,121].		
Carotenoids belong to the most efficient physical quenchers of singlet oxygen [55], but 
these molecules also are able to scavange other free radicals of different origins, like 
peroxide radicals [80,81,55]. However, not all beneficial effects of carotenoids are 
related to their antioxidant activity [122], it is also hypothesized that carotenoids or their 
derivatives can interact with cysteine residues of the IKK and/or NF-κB subunits and 
inactivate the NF-κB pathway, thus decreasing inflammatory pathways directly [42]. 
Other mechanisms by which carotenoids may be beneficial for human health are their 
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impact on cellular signaling and their ability to modulate gene expression 
[42,80,81,55,122,123]. Another hypothesis on carotenoids action is the stimulatory 
effects exerted by carotenoids on gap junction communication, which is thought to be 
implicated in the regulation of cell growth, differentiation and apoptosis [122]. 
 
Furthermore, carotenoids and their metabolites have been shown to impact gene 
expression and cell function through multiple mechanisms, including the 
interaction/interference with several transcription factors and the modulation of signaling 
pathways associated with inflammatory and oxidative stress responses [124]. 
2.5 Lutein 
 
2.5.1 Definition 
 
The carotenoid that this project is focused on, is lutein. Lutein is a non-pro vitamin A 
carotenoid from the family of xanthophylls or oxycarotenoids, named on the bases of 
oxygen being part of its structure [84,86]. The biochemical structure of lutein and its 
stereoisomer zeaxanthin can be described as a long polyene chain with alternate 
conjugated double bonds and attached methyl side groups. At both ends of the carbon 
backbone, lutein contains a cyclic hexenyl structure with an attached hydroxyl group 
[85,125]. This particular structure provides xanthophylls with certain polarity relative to 
hydrocarbon carotenoids, which allows these molecules to be oriented perpendicular to 
the lipid membrane with the end hydroxyl groups exposed to an aqueous environment 
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[126,127]. The presence of these hydroxyl groups is also believed to play a critical role 
in the biologic function of lutein and zeaxanthin [84]. 
 
The structure of lutein also accounts for the absorbance of certain wavelengths of the 
visual light spectrum, with a peak of absorption at 446 nm, and the emission at other 
wavelengths leading to the characteristic yellow-orange color of this molecule [84,85]. 
The concentration of lutein is therefore responsible for the yellow coloration of certain 
animal tissues, such as the adipose tissue, the egg yolk and the macula lutea of 
primates [125,128]. 
 
2.5.2 Sources, intake and absorption 	
In foods, lutein is particularly abundant in green leafy vegetables such as kale (40 
mg/100g) or spinach (12 mg/100g) and in yellow foods such as corn and egg yolks 
[84,129,130].  
 
Because lutein has one hydroxyl group on each ionone ring, it can be esterified with 
fatty acids in plant cells, resulting in mono- and di-acylated derivatives [131]. The most 
common fatty acid that esterifies lutein is palmitic acid, giving origin to lutein palmitate, 
which is the most common form of lutein in vegetable sources [84]. Conversely, animal 
sources contain mostly free or unesterified lutein [85]. 
 
According to the United States Department of Agriculture (USDA), on average, the daily 
intake of lutein by Americans is about 1-2 mg per day [84], which is 60% lower than the 
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6mg per day that has been associated with protection against AMD [132]. This amount 
is not easy to achieve through diet, however, in some populations such as the South 
Pacific Islanders, the intake of lutein can be as high as 25 mg per day [133].  
 
Once consumed, lutein has to be released from the food matrix and incorporated into 
mixed micelles which are molecular aggregates that transport fat-soluble nutrients, 
making them potentially accessible by the intestinal epithelium [112]. In humans, lutein 
is absorbed mainly in the small intestine, although in vitro studies have suggested that it 
is possible for lutein to also be absorbed in the colon [76]. The majority of the uptake of 
lutein by the enterocytes is thought to happen by simple diffusion.	 According to this 
mechanism, the micelles migrate through the unstirred water layer to the brush border 
membrane, where the micelles collide with the cellular membrane and lutein leaves the 
micellar structure and diffuses through the membrane into the cytoplasm of the 
enterocytes [86,102,112].  
 
However, results from several studies have suggested that carotenoid absorption 
follows a dose dependent, saturable process, which cannot be explained by a simple 
diffusion mechanism alone. This indicates the involvement of facilitated transport in the 
uptake of lutein [76,85,102]. The participation of a transporter also could explain why, 
when eaten with other carotenoids, there is a competition for intestinal uptake [76].    
 
Studies have reported the existence of receptor-mediated transport of lutein in the 
apical membrane of enterocytes, with strong indications for the involvement of the SR-
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BI, a member of the ABC transporter super-family [102]. This transporter is located in 
various tissues including the liver, testis, ovaries, and macrophages but it can also be 
found in the brush border membrane of the enterocyte from the duodenum to the colon 
[134]. At the intestinal level, SR-BI facilitates the uptake of free and esterified 
cholesterol, phospholipids, and triacylglycerol hydrolysis products, indicating low 
substrate specificity [85,116]. In 2005, Reboul et al. identified SR-BI for the first time to 
play a role in the uptake of lutein at the intestinal level using Caco-2 cells [135]. 
Another protein thought to be involved in the intestinal uptake of lutein is the NPC1L1 
[82]. This protein is widely expressed in human tissues, especially in the liver and the 
apical membrane of the enterocyte, where is the main cholesterol and phytosterol 
transporter [13]. A study done by During et al. [136] with Ezetimibe, a drug used to 
decrease dietary cholesterol absorption by inhibiting NPC1L1, showed that it 
significantly decreased the uptake of several carotenoids, including lutein in Caco-2 
cells [136]. These results suggest that lutein and cholesterol share transporters for 
uptake in the intestine. Once inside the enterocyte, lutein has three possible fates.  
A. Incorporation into chylomicrons: With most TG and dietary cholesterol, lutein is 
incorporated into CM and transported via the lymphatic system to the liver, where it 
can be stored or further packed into VLDL to be transported throughout the body 
[78,85,116]. 
B. Uptake by HDL particles: Unlike non-polar carotenes, that are mainly carried in 
LDL particles [130,137–139], xanthophylls including lutein and zeaxanthin are 
equally distributed between LDL and HDL particles [130,137–139].   Although lutein 
is thought to be absorbed exclusively via a chylomicron-mediated pathway and 
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transferred to HDL from VLDL via CETP, there is recent evidence that this 
carotenoid can also be incorporated into nascent HDL particles at the intestinal level 
[116,140]. In vitro studies with Caco-2 cells have shown that ABCA1 located at the 
basolateral membrane of enterocytes can transfer both lutein and zeaxanthin to 
apoA1, not to mature HDL [141]. These results are consistent with animal studies. 
For example, Niessor et al. reported markedly increased plasma and liver lutein and 
zeaxanthin in hamsters treated with the LXR agonist T0901317, which is an ABCA1 
inducer [141].  
C. Efflux: Some percentage of the lutein absorbed may be effluxed back to the 
intestinal lumen through ABC transporters such as ABCG5 and ABCG8. These are 
well known mediators of the excretion of dietary phytosterols [142].  However, 
ABCG5 polymorphisms have also been suggested to be associated with the lutein 
bioavailability from eggs in human subjects [143]. ABCG5 may excrete lutein and 
other highly polar epoxy xanthophylls to intestinal lumen [86]. Another transporter 
that may contribute to the efflux of lutein back to the lumen is the Multi-drug 
resistance protein 1 (MDR1), also known as P-glycoprotein, which is an efflux pump 
for lipid-soluble compounds and drugs [86,144]. It is suggested that the affinity of 
substrates for MDR1 is related to their polarity, and therefore highly polar 
xanthophylls such as lutein may be excreted by this membrane transporter [86]. 
 
2.5.3 Lutein bioavailability 	
As mentioned before, the intake of lutein from natural sources of lutein is low [84]. This 
low intake represents an obstacle to observe the bioactive effects of lutein in humans; 
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however, it is not the only challenge.  As with other carotenoids, the bioavailability of 
lutein varies widely among healthy subjects and depends on multiple factors, which 
means that serum concentrations are difficult to predict from dietary intake alone 
[82,85,101,145]. For example, although the total xanthophyll content in egg yolks is 1.2 
mg/100 g, which is low compared to the content in fruits and vegetables, the 
bioavailability is around 3 times greater than that from a vegetable source because it 
provides a fatty matrix and the lutein in animal sources is not esterified [85,129,146]. 
 
2.5.4 Lutein biological effects 	
Lutein and zeaxanthin are selectively taken up and accumulated in the macula, a small 
area of the retina responsible for central vision and visual acuity, and are the only 
carotenoids present in this tissue [84,147]. These xanthophylls are thought to be carried 
to the retina through HDL, which as mentioned before, is the lipoprotein primarily 
associated with lutein and zeaxanthin [85,148]. This specific relationship between HDL, 
lutein and the retina was shown in a study carried out by Connor et al. [137] using 
Wisconsin hypo alpha mutant (WHAM) chickens. These animals have very low levels of 
HDL due to a mutation in the ABCA1 gene and when these were fed a high-lutein diet, 
lutein concentrations increased in all tissues except the retina, suggesting the pivotal 
role of HDL in the delivery of carotenoids to retinal tissue [137,148]. 
 
Once in the retina, zeaxanthin is mostly found in the foveal region, whereas lutein is 
more abundant in the perifoveal region [149,150]. Together, these pigments are referred 
to as the macular pigment, where they provide protection to the retinal tissue against 
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the oxidative blue light [84,85,150,151]. It is no surprise that traditionally lutein and 
zeaxanthin are linked to eye health, specifically to the prevention of AMD 
[84,125,150,152,153] and other eye diseases, such as cataracts, retinal ischemia, 
uveitis, retinitis pigmentosa and diabetic rethinopathy [85,154,155].  
 
However, other potential benefits of lutein have been identified, since lutein may also 
protect against oxidative stress related diseases, such as atherosclerosis, diabetic 
microvascular complications and CVD [84,89,156,157]. Some authors have also found 
effects of lutein in the immune response and inflammation [85]. 
 Moreover, lutein is also found accumulated in the human brain and the concentration of 
carotenoid in this tissue has been positively correlated with cognitive function [158]. 
 
Lutein biological effects are due to its capacity to absorb blue light, which the most 
phototoxic visible light to which the retina is routinely exposed [159]. This explains why 
lutein is directly involved in eye health. The other mechanism is quenching ROS, which 
is why lutein has been related to a decreased risk for diseases where oxidative damage 
plays a role [84,85]. Lutein is very efficient in quenching lipid peroxide radicals [131]. 
2.6 The use of nano technology in nutraceutical delivery  
 
One approach to increase the absorption and bioavailability of lutein is the use of 
nanotechnology.	 Nanotechnology is the science that designs, synthesizes, 
characterizes and applies materials and devices on the nanometer scale (one-billionth 
of a meter) [160]. In the pharmaceutical and nutraceutical industry this technology is 
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applied in the formulation of carriers that protect bioactive agents, such as drugs, 
vaccines, genes and nutrients from degradation or inactivation [161,162].  
 
One of the most important applications for encapsulation of phytochemicals is to 
enhance their bioavailability by changing their pharmacokinetics and biodistribution 
[163,164]. Reviews on the influence of particle size on the biological fate of hydrophobic 
bioactive compounds, such as carotenoids, indicate that their bioavailability increases 
when the size of the particles encapsulating them are within the 100–1000 nm range. 
An increase in oral bioavailability is desirable since it means that a lower amount is 
needed to get the same biological effect [165]. 
 
2.6.1 Nanoemulsions 
One example of the application of nano technology in the encapsulation of lipid soluble 
compounds is the use of emulsion-based delivery systems. Oil-in-water (O/W) 
emulsions can be prepared by solubilizing the lipophilic bioactive components within the 
oil phase, and then homogenizing this with an aqueous phase containing a water-
soluble emulsifier or surfactant [162].  
 
Emulsions in general are non-equilibrium systems, therefore cannot be formed 
spontaneously and consequently, energy input	is required [166]. The size of the droplets 
produced depends on the composition of the system and the homogenization method 
used [162]. The formation of macroemulsions (where the droplet size is a few 
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micrometers) is fairly easy to achieve, however, to form droplets in the nano scale (20–
500nm) is difficult and requires a large amount of surfactant and/ or energy [167].  
 
Emulsions are thermodynamically unstable systems and their stability is affected mainly 
by four processes: creaming, coalescence, flocculation and Ostwald ripening [168]. 
However, due to their small droplet size, nanoemulsions have long term stability to 
these processes because the brownian motion and consequently the diffusion rate are 
higher than the sedimentation (or creaming) rate [166,169,170]. 
 
As mentioned before, carotenoids’ lipophilic nature and insolubility present challenges 
to their delivery and absorption [168]. Nanoemulsions are a promising technique to 
encapsulate carotenoids and overcome these challenges. This approach has been used 
with other lipidic nutraceuticals including delta-tocopherol, gamma-tocopherol, 
curcumin, lutein, lycopene, beta-carotene and astaxanthin, among others obtaining 
positive results [162,168,170–172].  
 
2.6.2 Nanoemulsion characterization and evaluation parameters  
There are many factors that need to be taken into account in order to assess the in vivo 
fate of nano-delivery systems, for example: particle size, surface area, particle number, 
aggregation/agglomeration state, charge, and surface coatings, among others, are all 
likely to influence the biological availability and effects of an administered nano particle 
[173].  
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Particle size 
The size of the particle is what makes nanotechnology so useful, and it is also one of 
the most important characteristics to evaluate [165,174]. Controlling the nanoparticle 
dimensions is important because it influences its physicochemical properties, functional 
performance and potential biological fate [165]. The same molecule, having a different 
size shows differences in particle uptake, deposition, and clearance [174,175].  
 
It is important to measure the particle size of a nanoemulsion droplets for scientific, 
technological, and regulation reasons. A variety of analytical techniques are available 
that are capable of providing information about the size of the particles in 
nanoemulsions, including static light scattering, dynamic light scattering, and electron 
microscopy [165]. 
Count rate: The count rate is the average number of photons detected per unit time in 
kilo-counts per second. This is useful for determining the sample quality, by monitoring 
its stability as a function of time [176]. 
 
Zeta potential: Zeta potential (ζ-potential) is a scientific term for electrokinetic potential 
in colloidal systems which has a major effect on the various properties of nano-drug or 
nano-nutrient delivery systems [177]. In other words, it is the electrostatic potential at 
the electrical double layer surrounding a nanoparticle in solution [175]. 
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Measurement of ζ-potential is currently a very straight forward way to characterize the 
surface of charged colloids, its unit is usually minivolts (mV) and the results from this 
measurement can give relevant information on concentration, distribution, adsorption, 
ionization, exposure or shielding of charged moieties [177].  Nanoparticles with a ζ-
potential between −10 and +10 mV are considered neutral, while nanoparticles with ζ-
potentials of greater than +30 mV are considered strongly cationic and of less than −30 
mV are considered strongly anionic [175].  
 
Polydispersity index 
Generally, nanoparticle samples contain a distribution of different sized particles.  It is 
therefore important to characterize both the central tendency and the degree of particle-
to-particle size variability present in the sample [175,178]. The polydispersity index, or 
PDI is a metric for size variability. The value of PDI ranging from 0 to 0.5 is said to be 
monodisperse and homogenous, whereas a PDI higher than 0.5 indicate 
nonhomogenity and polydispersity. Basically, the higher the value of PDI, the lower will 
be uniformity of the droplet size of the nanoemulsion.  Most authors accept PDI values 
less than 0.3 as optimal [179,180]. 
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3.1 Background 
 
The overall goal of this project was to evaluate the efficacy of a nanoemulsion of lutein 
in preventing cholesterol-induced hepatic steatosis and systemic inflammation using a 
guinea pig model.  As mentioned before, lutein is a non-provitamin A oxycarotenoid 
known for its antioxidant properties, which can be used in the prevention of many 
chronic diseases where oxidative stress plays an important role [1]. It has been shown 
that high fat diets and an excess of cholesterol induce oxidative stress and inflammation 
in animal models [2–5]. 
 
The effects of lutein in cholesterol-challenged guinea pigs have already been studied in 
our laboratory. After feeding guinea pigs a hypercholesterolemic diet (0.25% 
cholesterol) with or without 0.01g/100 g lutein, Kim et al. found that despite the 
expected injury caused by the cholesterol challenge, the animals receiving lutein had 
43% lower hepatic free cholesterol than the controls. Lutein fed guinea pigs also had 
lower expression of TNF-α and lower NF-κB DNA binding activity than the control group 
which indicates that lutein has anti-inflammatory properties and could be used as a 
dietary approach to prevent hepatic steatosis. Beneficial effects were observed also in 
the eyes, where lutein protected against cholesterol-induced oxidative stress and 
inflammation [6]. 
 
Furthermore, lutein also provided protection against atherosclerosis by significantly 
reducing aortic cholesterol and malondialdehyde concentrations, oxLDL in plasma and 
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the aorta, pro-inflammatory cytokines in plasma, and early signs of atherosclerotic 
lesions in the aorta of guinea pigs [7]. 
 
However, as with other lipophilic compounds, the absorption of lutein is dependent upon 
several factors, which makes it difficult to obtain a reliable prediction of its bioavailability 
from food sources and meals [8–10]. For this reason, several approaches to increase or 
obtain a consistent bioavailability of carotenoids like lutein have been studied [11]. 
 
One of these approaches is the use of nano technology and controlled delivery 
systems. The effectiveness of nano carriers as delivery systems is based on the 
encapsulation of phytochemicals to enhance their bioavailability by changing their 
pharmacokinetics and/or distribution patterns [12].	 In general, smaller particle sizes 
have been associated with increased bioavailability due to a greater surface to volume 
ratio [13–15].  
 
This was confirmed by Vishwanathan et al. [16] in two crossover human studies that 
compared a lutein supplement pill to two different doses of a lutein nanoemulsion added 
to orange juice (6mg/day in study 1 or 2 mg/day lutein in study 2). Each intervention 
was done for one week with a 2-week washout phase between treatments. The results 
showed that the mean serum lutein concentrations (n = 9) increased by 104% (P < 
0.001) after the 6 mg supplement and 167% (P < 0.001) after the 6 mg nanoemulsion 
phase. In study 2, mean serum lutein concentrations (n = 11) increased by 37% (P < 
0.05) with the 2 mg supplement and 75% (P < 0.001) with the 2mg nanoemulsion. The 
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use of a nanoemulsion resulted in 31% (P < 0.05) and 28% (P < 0.05) greater serum 
lutein concentrations compared to the supplement [16].  
 
Based on these previous studies, we hypothesized that the use of a nanoemulsion 
would increase the bioavailability of lutein and also be more effective than powdered 
lutein in reducing the detrimental effects of a cholesterol challenge in guinea pigs.  
 
3.2 Nanoemulsion preparation and characterization 	
In order to enhance the bioavailability of lutein, we used an emulsion-based delivery 
system. Oil-in-water (O/W) emulsions can be prepared by solubilizing lipophilic bioactive 
components within the oil phase, and then homogenizing this with an aqueous phase 
containing a water-soluble emulsifier [17]. 
 
For this case, we selected the use of d-alpha tocopheryl polyethylene glycol  succinate 
(TPGS) as a surfactant. TPGS is a water-soluble derivative of vitamin E, which is 
formed by esterification of alpha tocopherol succinate with polyethylene glycol [18]. 
TPGS is approved by the Food and Drug Administration as a safe pharmaceutical 
adjuvant and has been widely used as a solubilizer, oral absorption/bioavailability 
enhancer, emulsifier, and stabilizer in novel drug delivery systems with positive results 
[19]. 
 
The nano-emulsion was prepared by Designs for Health (Suffield, CT) using the 
following formula: 
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8.4% TPGS (Antares Health Products, Jonesborough, TN) 
11.2% medium chain triglyceride (MCT) oil (60:40 mix of caprylic acid:capric acids) 
70.4% water 
10.0% lutein powder at 5% (Maypro Industries, Westchester, NY) 
 
TPGS was first melted at 65-70°C on a stir plate, followed by the addition of the MCT 
oil.  Lutein powder was added next and stirred until thoroughly mixed. Lastly, water that 
had been previously heated to the same temperature was added.  The mixture was 
stirred on the stir plate until uniform, and then mixed with a high-speed homogenizer at 
12,000 rpm for 10 minutes.   
 
The nanoemulsion was characterized for particle size, ζ-potential and PDI. Particle size 
and PDI were measured using dynamic light scattering with a Zetasizer Nano ZS 
(Malvern, Westborough, MA), and ζ-potential was determined by laser Doppler micro 
electrophoresis technology with the same instrument. Samples were diluted 
appropriately with water to meet the sensitivity requirement of the equipment. 
 
Once characterized, the nanoemulsion was sent to Research Diets, Inc (New 
Brunswick, NJ) to be incorporated into the experimental diets required for the study.  
3.3 Experimental diets 
 
This project required the development of three different diets:  
A) CONTROL: a pelleted non-purified diet that met all the nutritional requirements 
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for guinea pigs plus 0.25% of dietary cholesterol, which is sufficient to ensure 
liver damage in the proposed time frame of the experiment [20].  
B) POWDERED LUTEIN (PL): a pelleted non-purified diet that matched to the 
control plus 5% powdered lutein, for a final concentration of 0.02% lutein by 
weight (Maypro Industries, Westchester NY).  
C) NANO: a non-purified diet matched to control plus a nanoemulsion of lutein, 
previously prepared by Designs for Health (Suffield, CT), for a final concentration 
of 0.02% lutein. 
 
For all diets, all ingredients were homogeneously mixed with water (5% by weight), 
dyed, and pelleted via cold extrusion process.  After pelleting, diets were dried at 88-
92°F for 2 days to remove excess water. The complete diet composition is presented in 
Table 3.1.  
 
For the confirmation of the presence of lutein in food a quantitative analysis was 
performed in triplicate for the three diets. For each trial, the weight of a single pellet of 
food was recorded. The pellet was then placed in a glass vial and 5 mL of technical 
grade acetone was added. Each pellet was pulverized manually with a metal rod and 
then allowed to soak in the acetone for 1 hour over ice in a dark room. After this time, 
the samples were gently pipetted into eppendorf tubes and centrifuged for 2 min at 
13,600 x g. The supernatant was then transferred to a clean glass vial, and the 
absorption spectra were measured using acetone as blank. Lambert-Beer’s Law was 
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used to determine the concentration of lutein in the individual pellets, and from this the 
concentration of lutein in mg per g of feed was extrapolated [21]. 
3.4 Animal model 
 
For this project, we used the guinea pig (Cavia porcellus) model challenged with 0.25% 
cholesterol, which is equivalent to 1800 mg/day in humans [20].  
 
The guinea pig is a very good model to study cholesterol and lipoprotein metabolism 
[22]. One of the main reasons is that unlike other animal models, guinea pigs have a 
very similar cholesterol distribution in plasma when compared to humans, which means 
that they carry most of their cholesterol in LDL [22,23]. These animals also have hepatic 
cholesterol metabolism comparable to what is observed in humans [24]. Other studies 
have reported the deleterious effects of dietary cholesterol in guinea pigs as their LDL 
and hepatic cholesterol increase in a dose-dependent manner [25,26]. 
 
For this project, twenty-four male Hartley guinea pigs weighing between 200 to 300 
grams were housed in pairs in a light cycle room. During the first week of acclimation, 
the animals received a regular chow diet and water ad libitum. After acclimation, the 
cages were randomly assigned to one of three groups: CONTROL, POWDERED 
LUTEIN (PL) or NANO for a total of 4 cages/8 guinea pigs per group. The experimental 
diets were introduced gradually (25%, 50%, 75% and 100%) by mixing them with the 
regular chow to avoid food aversions in the guinea pigs. After a week, once the animals 
were consuming 100% experimental diets, the 6-week trial started.  
	 56	
 
Food consumption was monitored three times a week, weighing the food left on the 
feeder and subtracting that amount from the amount given two days prior. Once a week, 
the guinea pigs were weighed to evaluate growth and overall health.  
 
After 6 weeks, guinea pigs were fasted for 12 hours to prepare them for sacrifice. Each 
animal was anesthetized via inhalation of isoflurane (1-chloro-2,2,2-trifluoroethyl 
difluoromethyl ether) [27]. When no response was observed after an extremity pinch the 
guinea pigs were killed with the heart puncture technique [28] in order to collect a large 
volume of good quality blood.  
 
The blood collected from the heart was centrifuged immediately (2000 x g for 20 mins) 
to separate the plasma. Aortas, livers, eyes, and epididymal adipose tissue were also 
collected and preserved at -80°C for further analysis. 
 
All animal experiments were performed in accordance with U.S. Public Health Service/ 
U.S. Department of Agriculture guidelines. Experimental protocols were approved by 
the University of Connecticut Institutional Animal Care and Use Committee, protocol 
#A11-023.  
 
 
2.5 Results and discussion 
 
2.5.1 Characterization of the nanoemulsion 
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In this study, the nanoemulsion diluted 1000 times had an average size of 165.4 nm 
(Fig 2.1) and a PDI of 0.195. A PDI of 0 to 0.5 indicates a narrow distribution [29]. Our 
lutein nanoemulsion fell within this range, suggesting that the particle size distribution 
was uniform [30]. For nanoemulsions, the desired PDI is < 0.3, as higher values have 
shown to increase Ostwald ripening and decrease stability [13,31].  
 
ζ-potential is another important parameter of nano preparations. This value is an useful 
indicator of particle surface charge, which can be used to predict and control the 
stability, performance, and pharmacokinetic properties of colloidal suspensions or 
emulsions [14,32,33]. The nanoemulsion used in this study had a ζ-potential of -40.5 
mV, which may be explained by the potent emulsification effect of TPGS, which 
solubilized MCT, resulting in the exposure of carboxyl groups on the fatty acids in the 
aqueous phase.  
 
It is currently accepted that ζ-potentials under |30|mV are optimum, while potentials 
between |5| and |15|mV are in the region of limited flocculation; and between |5| and 
|3|mV of maximum flocculation. Thus, high values of ζ-potentials prevent particle 
aggregation and flocculation of a colloidal dispersion [33].  Our data indicates that the 
prepared lutein nanoemulsion consisted of well-distributed oil droplets with excellent 
storage stability. 
 
2.5.2 Food intake 
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During the intervention, the guinea pigs consumed an average of 17 grams of food per 
day, which is equivalent to 3.5 mg of lutein/day for both PL and NANO groups. There 
was no difference in food intake (pooled mean ± SE: 17 ± 4 g/d) or final body weight 
among groups during the intervention (pooled mean ± SE: 528 ± 48 g) (Table 3.2). 
 
2.5.3 Liver and adipose weight 
There was no difference in weight of epididymal adipose tissue between groups. 
However, livers of the NANO group weighted less than the ones from other groups. 
Higher liver weight has been suggested to be correlated with increased hepatic TG, 
diglycerides, CE, and FC concentrations [2,34] Data are shown in Table 3.2. 
 
2.6 Strengths and limitations 	
Strengths of this study design include the use of an animal model that mimics 
cholesterol metabolism in humans [22–24]. The guinea pig’s size also facilitates the 
sacrifice process and tissue collection. This model has been used numerous times to 
evaluate the effects of low carbohydrate diets [20,35,36], fiber [37], cholesterol [35], 
dietary fat [26,38] lutein [6,7] and polyphenols [39], among others on various measures 
of health.  	
The main limitation of the study design was the lack of an empty vehicle control group. 
This addition would allow for an account of the effects of the components of the 
nanoemulsion without the lutein. In this particular nano formulation, there are two main 
components that could have influenced the results presented in this work: TPGS and 
MCT oil.  
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As mentioned previously, TPGS is esterified α-tocopherol succinate with polyethylene 
glycol 1000. TPGS, unlike free tocopherols, is water soluble and has been used to 
enhance the bioavailability and solubility of drugs and lipophilic compounds due to its 
capacity to form micelles and be absorbed without the need of bile salts [40]. However, 
TPGS can be also used as a vitamin E supplement [41,42] because the compound can 
release free tocopherol in the intestinal cell that can be absorbed and transported in 
lipoproteins like regular vitamin E [43]. Some authors have also reported that vitamin E 
can have synergistic effects with carotenoids, enhancing their antioxidant capacity [44]. 
 
Due to their lipophilic characteristics, intestinal absorption of carotenoids is enhanced by 
the presence of dietary lipids in the meal [45,46]. In this case, the absorption of lutein 
may have been facilitated by the presence of MCT in the nanoemulsion. Dietary fat 
facilitates solubilization, micellarization, and packaging of dietary carotenoids into 
chylomicrons [10,47]. In addition to the amount of fat, the structural characteristics of 
the dietary lipids also influence carotenoid bioavailability. Fatty acid chain length and 
degrees of saturation differ in their ability to enhance carotenoid absorption [47]. MCT 
contains fatty acids of 6 to 12 carbons and differ from long chain triglycerides in that 
they are absorbed directly into the portal circulation and transported to the liver without 
needing chylomicrons [48]. Some authors suggest that the presence of MCT could not 
only increase the bioavailability of carotenoids, but also affect their tissue distribution 
[47].  
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TABLES 
Table 3.1 Composition of the experimental diets  
Component Control PL NANO 
 
g/100 g % Energy g/100 g % Energy g/100 g % Energy 
Protein1 22.2 23 21.3 23 22.1 23 
Carbohydrate 40.5 41.9 38.8 41.9 40.4 41.9 
Fat2 15.1 35.1 14.4 35.1 15 35.1 
Vitamins3 1.1 - 1.1 - 1.0 - 
Minerals3 8.1 - 8.1 - 7.8 - 
Cellulose 10.8 - 10.8 - 10.4 - 
Guar Gum 2.7 - 2.7 - 2.6 - 
Cholesterol 0.25 - 0.25 - 0.25 - 
Lutein 
Powder 4 0 - 0.021* - - - 
Nano-Lutein5 
0 - 0 - 0.021* - 
1 Soybean protein + 0.5 g/100g L-Methionine  
2 Fat mix was olive oil-palm kernel oil-safflower oil, high in lauric and myristic acids as previously 
reported [49] 
3Compostion of vitamin and mineral mixes have been previously reported [50] 
4 Powdered lutein provided by Maypro Industries 
5 Nano-emulsion prepared by Designs for Health, Suffield, CT 
*0.021% is equivalent to an intake of 3.5 mg of lutein per day based on food consumption 
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Table 3.2 Food intake, body, liver and adipose tissue weights of guinea pigs fed a 
hypercholesterolemic diet with no lutein (control) powdered lutein (PL) or nano-
lutein (NANO)1 
 Control PL NANO 
Food intake (g/d) 16.7±0.9 18±1.0 16.0±1.3 
 
Body Weight (g) 
 
534.8±44 
 
543±54 
 
507±43 
 
Liver weight (g) 
 
Adipose weight (g) 
 
 
24.6±2.8a 
 
2.8±1.2 
 
26.3±3.9a 
 
3.8±1.1 
 
21.5±2.9b 
 
5.6±7.1 
 1 Values are means ± SD, n=8. Values in the same row with different superscripts are 
significantly different at P< 0.05.  		
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FIGURES  
 
Figure 3.1 Average particle size distribution of the lutein nanoemulsion with a 
1000X dilution 
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Chapter 4 
Evaluation of bioavailability of a nanoemulsion of 
lutein 
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4.1 Background 
 
Many compounds found naturally in foods are thought to have beneficial effects on 
human health. However, these potential benefits, usually studied in vitro, are not 
observed in vivo because these compounds have relatively low and/or variable oral 
bioavailability [1–3]. Upon oral consumption, a certain percentage of micronutrients and 
phytochemicals are not absorbed. Bioavailability is defined as the fraction of an 
ingested nutrient that is available for utilization in normal physiological functions or for 
storage [4,5]. It is a complex concept, because it entails many processes from ingestion 
to delivery to the target organ or tissue while there is a wide variety of affecting factors 
[5]. Bioavailability can be further classified into four different steps which are 
bioaccessibility, absorption, tissue distribution, and bioactivity [6]. Bioaccessibility is the 
amount of ingested nutrient that is available for absorption in the intestine. This is the 
first challenge on improving bioavailability of nutrients, specifically carotenoids, because 
often the inefficient release from the food matrix results in poor absorption, and limited 
biological activity [7,8].  
 
Bioavailability is usually measured by the amount of nutraceutical that is present in 
serum or plasma after ingestion. However, in the case of carotenoids, the concentration 
in plasma represents about 1% of the total body carotenoid content, whereas the 
majority of carotenoids are found in the liver [4]. This is why measurement of the 
concentration in target organs rather than plasma is a better way to understand the 
bioavailability of these compounds.  
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Multiple approaches have been taken to improve the bioavailability of nutraceuticals and 
increase the potential health benefits of these compounds without increasing the 
dosages. One of these approaches is the use of nanotechnology to encapsulate a 
poorly-absorbed compound to preserve its native properties over time and enhance its 
absorption [9]. Liposomes, micelles, nanoemulsions and polymeric nanoparticles have 
been tested for efficacy and safety, demonstrating a broad variety of useful properties 
[10]. Nanoemulsions are a class of small droplets usually in the range from 50 to 200nm 
[11]. The physicochemical characteristics (e.g., composition, dimensions, structure, 
charge, and physical state) of these nanoemulsions can be controlled by selection of 
appropriate ingredients and fabrication techniques, depending on the compound 
encapsulated and the desired effect of the preparation [12].  
 
Nanoemulsions of lutein have been studied before with positive results [13]. In this 
project, the nanoemulsion described in chapter 3 was tested in terms of efficacy for 
increasing the bioavailability of lutein. Our hypothesis was that the nanoemulsion would 
improve the bioavailability of lutein, measured as lutein concentration in plasma and 
three target tissues: eyes, liver, and adipose. 
4.2 Methods  
 
4.2.1 Lutein extraction from plasma and tissues:  
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To assess the bioavailability of lutein in the three experimental groups mentioned in 
chapter 3, carotenoids were extracted from plasma, liver, adipose tissue and eyes and 
measured by high performance liquid chromatography (HPLC). 
 
For plasma, the method followed is described by Blesso et al. [14]. Briefly, 200 µl of 
plasma was added into a 16x100 mm screw cap glass vial, followed by the addition of 
150 µL of internal standard (trans-b-apo-8’-carotenal, Sigma Aldrich) diluted in ethanol, 
500 µL of saline solution, and 2mL of a mixture of chloroform:methanol (2:1 v/v). The 
vials were then vortexed for 30 seconds and centrifuged at 2000 rpm for 10 mins at 4°C. 
After centrifugation, the chloroform layer was transferred to another vial using a Pasteur 
pipette. To the first vial, 3 mL of HPLC grade hexane was added to extract any 
remaining carotenoids. The vials were vortexed for 40 seconds and centrifuged at 2000 
rpm for 10 min at 4°C. The organic phase was transferred to the vial containing 
methanol and dried under nitrogen gas in a 40°C water bath. The dried carotenoids 
were reconstituted in 150µL absolute ethanol and sonicated for 30 seconds. The 
reconstituted samples were transferred from the glass tube into a 1.5 mL amber 
microcentrifuge tube and spun at 14000 rpm for 10 min at 4°C. Finally, 150 µL of each 
solution was transferred to an amber HPLC vial. 
For tissue samples, methods were adapted from Schmitz et al. [15].  Approximately 1 g 
of adipose tissue and liver or one eye were transferred to a 50-mL centrifuge tube 
containing 5 mL of an ethanol:water mixture (50:50 v/v) with 1% butylated 
hydroxytoluene (BHT) added as an antioxidant. Tissues were then homogenized 
completely with a tissue homogenizer followed by the addition of 5 mL 10% sodium 
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hydroxide (NaOH) in ethanol to the resulting slurry. The samples were mixed and 
saponified in a 60°C water bath for 30 min.  All samples were then cooled in an ice bath 
and 10 mL of distilled water was added. 200 µl of this mixture was transferred to a glass 
vial and 150 µl of the internal standard was added. Each sample was extracted three 
times with 10 mL of hexane, with a centrifugation at 2000 rpm for 10 mins at 4°C after 
each extraction. Hexane was evaporated with nitrogen gas in a 40°C water bath and 
carotenoids were reconstituted with ethanol and transferred to an amber HPLC vial as 
detailed above. Analysis of plasma and tissue extract was completed within 48 h of the 
extraction. 
 
4.2.2 HPLC analysis  
  
Lutein analysis was conducted using a Dionex UltiMate 3000 UHPLC with a YMC 
Carotenoid 3 µm, 4.6 x 150mm column with a guard column. The autosampler was 
maintained at 5°C and the column oven at 25°C. The flow rate was 1 mL per minute for 
a total run time of 55 minutes. Mobile phases were (A) Methanol: Methyl tert-butyl ether 
(MtBE):ammonium (NH4) acetate in water (83:15:2) and (B)  Methanol:MtBE:NH4 
acetate in water (8:90:2). Mobile phase flow followed a gradient from 0-100% B over the 
55 minute run time. 
4.2.2 Statistical analysis  
Differences between groups were analyzed by One-Way ANOVA with Fisher’s LSD 
post hoc analysis. P < 0.05 was considered to be significant. Data are presented as 
mean ± SD. All analyses were conducted on SPSS for Windows, Version 20 (IBM 
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Corp.) 
4.3 Results 
 
 
The NANO group had a significantly higher concentration of lutein in both plasma (Fig 
4.1) and liver (Fig 4.2) compared to the other treatments (P < 0.001). In contrast, 
although a trend is observed, there were no differences in lutein concentration between 
the lutein and NANO groups in the eyes (Fig 4.3) or the adipose tissue (Fig 4.4). 
However, carotenoid concentration in both PL and NANO were higher than the control 
group in these tissues (P < 0.05).  
4.4 Discussion 
 
In this study, we have demonstrated that a nanoemulsion of lutein is more bioavailable 
than regular powdered lutein in guinea pigs, as high concentrations of this carotenoid 
were found in liver and plasma from the NANO group. Similar results have been 
reported in humans, where a nanoemulsion of lutein was found to be associated with 
higher concentrations of plasma lutein [13]. Similarly, nanoemulsions have been used 
effectively with other lipid soluble compounds, such as β-carotene [16] and vitamin E 
[17], denoting the efficacy of this technology in increasing the absorption of poorly 
bioavailable compounds.   
 
In this particular case, the use of TPGS as a surfactant could have also contributed to 
the increased bioavailability of lutein via inhibition of MDR1. As previously described, 
MDR1 is major efflux pump for lipid soluble compounds located, among other sites, in 
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the apical membrane of enterocytes, and it has been proposed that once absorbed, 
xanthophylls such as lutein may be effluxed back into the intestinal lumen via this 
transporter [18]. TPGS has shown to be an efficient MDR1 inhibitor in studies with 
several drugs, which resulted in an increased bioavailability of the compounds tested 
[19]. This is one of the reasons why TPGS has been extensively used in drug delivery 
studies and probably on of the reasons why, in the present study, there was more lutein 
in liver, plasma, eyes and adipose tissue of the guinea pigs of the NANO group when 
compared to controls and in plasma and liver when compared to PL.  
 
Another possible explanation for the increased bioavailability of lutein is that 
nanoemulsion droplets have a higher surface area of the lipid phase exposed to the 
surrounding aqueous phase, which increases their lipid digestion rate [20,21]. This can 
be translated into more lutein available for absorption at the apical membrane of the 
intestinal cells. Moreover, studies have shown that, particularly for lutein, a slow transit 
time in the gastrointestinal tract is correlated with higher absorption [22]. One of the 
characteristics of nanoparticles is that their small size allows them to penetrate the 
intestinal mucus layer and become trapped (mucoadhesion), allowing more time for 
lutein, in this case, to be released and absorbed by the enterocyte [12,20].  
 
An interesting observation is that lutein is selectively accumulated in eye tissues. 
However, in this particular study, although a trend is clear, there is no significant 
difference between the concentration of lutein in the eyes of the guinea pigs from the 
NANO group and the PL group. However, it is important to clarify that lutein and its 
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stereoisomer zeaxanthin are concentrated in the macular region of human and 
nonhuman primates, while guinea pigs, as with many other rodents, do not have a 
macula and lack major retinal vessels [23,24]. Therefore, it is unsurprising that the 
relationship between plasma lutein concentrations and eye lutein concentrations are not 
congruent. Nevertheless, lutein can also be found in small concentrations in the eye 
lens, which is why, despite the absence of a macula, lutein was found in both PL and 
NANO groups [25].  
 
As mentioned previously, most carotenoids in the body are stored in the liver [4], where 
we found  a higher concentration of lutein in the NANO group compared to the two other 
groups. This could explain why there was a lower concentration of this carotenoid in the 
adipose tissue when compared to the liver (Fig 4.2 and Fig 4.4). Furthermore, other 
researchers have found that lutein is preferentially accumulated in the liver, with less 
distribution in the adipose tissue, which is in agreement with our results [26,27]. 
 
 
4.5 Strengths and limitations 
 
The main strength of this part of the study is the use of different tissues to measure 
bioavailability. This gives detailed information about the biological fate of lutein. 
Knowing that this carotenoid is preferentially accumulated in the eye in humans opened 
not only an entire area for research, but also a market for supplementation for the 
prevention of AMD and other eye diseases [25,28,29]. Since lutein is a potent 
antioxidant, it is possible that an alternate use of lutein supplementation would be for 
the prevention of liver diseases in which oxidative stress plays a major role.  
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One limitation of this study is the lack of other tissues of interest, such as spleen or 
brain, to evaluate lutein distribution. The most important tissue to collect would have 
been the intestine, in which we could have measured MDR1 expression and activity.  
 
One reason why some tissue results were not significant, despite the evident trend, is 
the variability within the groups. This can be explained by the fact that the animals were 
eating ad libitum and they were caged in pairs, so the amount of lutein consumed by 
each individual animal may differ significantly, especially between paired guinea pigs, 
because there is usually dominance of one animal over the other. For feeding studies, 
oral gavage is usually the best choice, however, the guinea pig is not a good model to 
apply this technique as it tends to be painful and usually causes digestive tract injury or 
death by airway perfusion [30]. Also, more animals in each group could have added 
power to the statistics to reach significance in the trends.   
 
Another limitation is the fact that the nanoemulsion added fat to the guinea pigs’ diet. 
This addition may be also responsible for the increased absorption of lutein because, as 
mentioned before, this xanthophyll is very sensitive to the presence of lipids in the meal 
[31]. This could have been controlled by having a group of guinea pigs with added the 
same amount of MCT oil but not in the form of a nanoemulsion. However, the diet was 
15% fat, which represents 2.55 grams of fat per day per guinea pig, since they ate 17 
grams of food per day. With the nanoemulsion, which is 0.02% of the total diet and 
11.2% MCT oil, this amount only increases by 0.04 grams of fat per day, which cannot 
	 75	
explain the significant increase of lutein absorption observed in the NANO group. 
Further studies with this preparation need to be done to clarify this issue.   
4.6 Conclusions 
 
For the results presented in this chapter, we conclude that the nanoemulsion used for 
this study did increase the bioavailability of lutein, as evidenced by a significantly higher 
concentration in all tissues when compared to control and in liver and plasma when 
compared to both control and PL groups. This suggests that nanoemulsions could be a 
promising approach to increase the biological effects of lutein in humans. Our results 
also suggest that this lutein nanoemulsion could be used as a supplement or as an 
ingredient in functional foods.  
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FIGURES 
 
Figure 4.1 Concentration of lutein in plasma of guinea pigs fed no lutein (control), 
powdered lutein (PL) (3.5 mg/d), or lutein nanoemulsion (NANO) (3.5 mg/d) for 6 
wks. Values are mean ± SD, n = 8. Bars without a common letter differ at P < 0.05			
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Figure 4.2 Concentration of lutein in livers of guinea pigs fed no lutein (control), 
powdered lutein (PL) (3.5 mg/d), or lutein nanoemulsion (NANO) (3.5 mg/d) for 6 
wks. Values are mean ± SD, n = 8. Bars without a common letter differ at P < 0.05. 	
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Figure 4.3 Concentration of lutein in eyes of guinea pigs fed no lutein (control), 
powdered lutein (PL) (3.5 mg/d), or lutein nanoemulsion (NANO) (3.5 mg/d) for 6 
wks. Values are mean ± SD, n = 8. Bars without a common letter differ at P < 0.05.						
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Figure 4.4 Concentration of lutein in adipose tissue of guinea pigs fed no lutein 
(control), powdered lutein (PL) (3.5 mg/d), or lutein nanoemulsion (NANO) (3.5 
mg/d) for 6 wks. Values are mean ± SD, n = 8. Bars without a common letter differ 
at P < 0.05.  			
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Chapter 5 
 The effects of a nanoemulsion of lutein on 
cholesterol-induced hepatic damage 
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5.1 Background 
 
The generation of reactive ROS plays an important role in producing liver damage. ROS 
disrupt lipids, proteins and DNA and moreover, ROS induce necrosis, apoptosis of 
hepatocytes and amplify the inflammatory response [1]. As mentioned previously, 
normal hepatic metabolism produces ROS, however, external factors such as drugs, 
alcohol, environmental pollutants and in this case, a cholesterol challenge also generate 
oxidative stress [2,3]. Kupffer cells, hepatic stellate cells and endothelial cells are 
particularly sensitive to oxidative stress-related molecules, including OxLDL [4].  Pro-
inflammatory cytokines such as TNF-α can be produced in Kupffer cells induced by 
oxidative stress, and create an inflammatory response or even induce apoptosis [1,2].  
 
Because the increasing prevalence of NAFLD, many natural dietary compounds have 
been widely studied for prevention and treatment of this disease. Among these, 
carotenoids such as lycopene, beta-carotene, astaxanthin and lutein have been studied 
[5–8]. The exact mechanisms of the protective effects of carotenoids in NAFLD are not 
completely understood but it is hypothesized that their potential relies on their 
antioxidant and anti-inflammatory properties [9].  
 
The effects of lutein on cholesterol-induced liver damage has been tested previously in 
our laboratory by Kim et al. [7]. After feeding guinea pigs a hypercholesterolemic (0.25% 
(wt:wt) cholesterol) diet with or without 0.1% (wt:wt) lutein, equivalent to 3 mg/lutein/day, 
Kim et al. found that despite the expected injury induced by the cholesterol challenge in 
all animals, the ones supplemented with lutein had 43% lower hepatic FC than the 
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controls. Lutein fed guinea pigs also had lower protein concentration of TNF-α and 
lower NF-κB DNA binding activity than the control group, suggesting that lutein exerts 
anti-inflammatory effects in hepatic tissue [7]. 
  
Our hypothesis for this project is that a nanoemulsion of lutein would increase the 
absorption of this xanthophyll, making it more effective than regular powdered lutein in 
reducing cholesterol-induced liver damage with an intake of 3.5 mg/lutein per day in 
guinea pigs.  	
5.2 Materials and methods 
 
5.2.1 Liver Enzymes: alanine aminotransferase (ALT), and aspartate aminotransferase 
(AST) were measured using a Cobas C 111 analyzer (Roche Diagnostics, Indianapolis, 
IN). This instrument uses direct enzymatic reactions and photometric detection.   
 
5.2.3 OxLDL: Tissue total protein was extracted using RIPA buffer and total protein 
concentration of the lysates were determined using the BCA Protein Assay Kit (Cell 
Signaling Technologies Inc, Beverly, MA) [10]. Using the same concentration of protein 
for all samples hepatic OxLDLs were measured with a specific guinea pig OxLDL ELISA 
kit (MyBioSource, Inc, San Diego California) according to manufacturers instructions.  
 
5.2.4.Cholesterol Concentration in Hepatic Tissue: 10 mg of liver for each sample was 
homogenized with 200 µL of chloroform/isopropanol/MP40 (7:11:01). The slurries were 
centrifuged and the supernatant was dried at 50°C overnight. The quantification for total 
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(TC) and free cholesterol (FC) were done with enzymatic assay kits (Wako Diagnostics, 
CA) according to Carr et al. [11] The esterified cholesterol (EC) fraction was calculated 
manually by subtracting FC from TC. [12] 
 
5.2.5 Histologic Evaluation: Small pieces of liver tissue were immersed in 10% buffered 
formalin. Formalin-fixed livers were paraffin embedded and 3–5 µm sections were 
stained with hematoxylin and eosin. Histologic evaluation was performed on two 
separate occasions by a veterinary pathologist blinded to the treatments, using a semi-
quantitative scoring system to assess the severity of hepatic steatosis and inflammatory 
cell infiltration in 10 microscopic fields examined at 200X [13]. The following criteria was 
used for scoring hepatic steatosis: grade 0, no fat; grade 1, fatty hepatocytes occupying 
<33% of the hepatic parenchyma; grade 2, fatty hepatocytes occupying 33–66% of the 
hepatic parenchyma and grade 3, fatty hepatocytes occupying >66% of the hepatic 
parenchyma [13,14].  
 
5.2.6 Inflammatory Cytokine Concentration in Liver:  Tissue total protein was extracted 
using RIPA buffer and total protein concentration of the lysates were determined using 
the BCA Protein Assay Kit (Cell Signaling Technologies Inc, Beverly, MA) [10]. Using 
the same concentration of protein for all samples, the following cytokines were 
measured using Luminex technology (Luminex MAGPIX System, Austin, TX) with the 
MILLIPLEX MAP Rat Cytokine Immunoassay kit (Millipore corporation, Charles, MO, 
USA): IL-1β, IL-6, IL-10, IFN-γ, MCP-1, and TNFα, as previously described [15]. 
 
	 87	
5.2.7 Gene expression 
Primers design: Specific primers (Table 5.1) for Cavia porcellus were designed with the 
National Center for Biotechnology Information website. 
Nucleic Acid Extraction: Liver tissue (~100mg) were homogenized and RNA was 
extracted with the Trizol® (Thermo Fischer Scientific, Waltman, MA) method [16] . 
cDNA was synthesized and amplified and quantified using real time PCR using a Bio-
Rad CFX96 Real-Time system (BioRad, Hercules, CA). 
RT-qPCR: Housekeeping genes were analyzed for threshold cycles (Ct). Each gene of 
interest was analyzed for relative expression using the same reaction mix and then 
standardized the gene of interest’s Ct to the geometric mean of the Ct of the 
housekeeping genes using the 2-ΔΔCt. 
 
5.2.8 Statistical Analysis 
Differences between groups were analyzed by one-way ANOVA and Fisher’s LSD post 
hoc analysis. All analyses were conducted on SPSS for Windows, Version 20 (IBM 
Corp.) 
5.3 Results 
 
5.3.2 Liver enzymes 
For liver enzymes, there was no difference between AST activity between groups; 
however, ALT was significantly lower in both the PL and the NANO groups when 
compared to the controls (Figure 5.1) 
5.3.3 Hepatic lipids, Liver Inflammation and Steatosis  
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Hepatic total cholesterol and esterified cholesterol concentrations were lower in the 
NANO group (Table 5.2). There were no differences in hepatic cytokines IFNγ, IL-6, IL-
10, MCP-1 or TNFα)among groups except for IL-β, which was lower in both lutein (32.3 
±9.1 ng/g) and NANO groups (26.4±7.0 ng/g) when compared to controls (45.4±16.8 
ng/g) (P < 0.05) (Table 5.3). 
 
Histologic evaluation of steatosis showed that the NANO group had a lower steatosis 
score (1.8±0.83) when compared to both lutein (2.75±0.46) and control (2.6±0.52) (P < 
0.05). This attenuated accumulation of liver lipids in the NANO group is also shown in 
Figure 5.2 where the arrows show lipid droplets in the hepatic tissue. A marked 
reduction in the degree of steatosis was observed in the livers from the guinea pigs fed 
the lutein nanoemulsion while there was no apparent difference between the groups fed 
powdered lutein (PL) or no lutein (control) (Figure 5.3).  
 
5.3.4 Oxidative stress markers  
Oxidative stress was assessed by the measurement of OxLDL in hepatic tissue. As 
shown in Figure 5.4, both PL and NANO groups showed a lower concentration of 
OxLDL (9.1±4.3 ng/mg and 12.3±4.3 ng/mg, respectively) when compared to the control 
group (21.7±14.4 ng/mg). 
 
5.3.5 Hepatic gene expression 
According to the results from qRT-PCR, the relative gene expression of acyl-coenzyme 
A:diacylglycerol acyltransferase 2 (Dgat2) was lower in the NANO group when 
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compared to the control group (P<0.05). In terms of cholesterol metabolism related 
genes, guinea pigs from the PL group, but not the NANO group, showed a higher 
expression of the sterol regulatory element-binding protein 2 (Srebpf2). Figure 5.5. No 
other differences in gene expression were observed among groups in the tested genes. 	
5.4 Discussion 	
 
5.4.1 Liver enzymes 
ALT and AST are enzymes involved in amino acid and protein metabolism that are 
commonly used as markers for liver damage because when there is hepatic injury, 
these enzymes leak to the bloodstream leading to their detection in plasma [17–19]. 
Previous studies have shown that lutein can decrease cholesterol induced liver damage 
in guinea pigs [7] and in this study, a similar effect was observed for ALT, but not AST, 
in both  PL and NANO groups (table 2). The reduction in only ALT can be explained by 
the fact that both enzymes are highly concentrated in the liver although AST is also 
diffusely present in the heart, skeletal muscle, brain and kidneys suggesting that 
elevations in plasma ALT is more specific for liver injury [17]. This hepato-protective 
action of lutein may be due to this carotenoid’s capacity to scavenge reactive oxygen 
radicals and thus, decreasing oxidative stress in the hepatocytes, which can be 
translated into less ALT leakage and activity [20].  
 
5.4.3 Liver lipids and Histologic evaluation 
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Previous studies have shown that a cholesterol challenge leads to hepatic steatosis in 
animal models [21,22]. As mentioned before, hepatic steatosis is mostly an 
accumulation of TG and fatty acids in the hepatocytes; however, lipidomic studies have 
shown an increase in hepatic FC concentration can accelerate the development of 
NAFLD and NASH [23]. Mechanistically, this FC may activate macrophages and also 
contribute to lipotoxicity and liver injury [24,25]. Hepatic cholesterol accumulation can be 
attributed to an up-regulation of  LDL-R via activation of sterol regulatory element 
binding protein 2 (SREBP-2), reduced biotransformation to bile acids, and suppression 
of canalicular pathways for biliary cholesterol and bile acid excretion [24]. 
 
In the current study, the NANO group showed a lower concentration of hepatic TC and 
CE, however, no differences were found in FC concentrations. In the histological 
evaluation, nevertheless, the livers of the NANO group were considered to have lower 
steatosis score which is paradoxical because hepatic steatosis means excessive 
deposition of fat in the liver, and in our results this only coincides with the results 
reported for TC and EC [26].  
 
Regarding the differences found in cholesterol, it is possible that in the NANO group, 
the excess cholesterol was mobilized to extra-hepatic tissues via VLDL, which could 
explain both the reduction of cholesterol in the hepatocytes and the higher number of 
VLDL particles found in plasma (reported in the next chapter).  
 
5.4.4 Hepatic inflammatory markers  
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Besides being a potent antioxidant, lutein has shown to exert anti-inflammatory effects 
[7,27]. Although many cytokines were evaluated, significant differences were only 
observed in the case of IL-1β. Both lutein treatments resulted in a lower concentration of 
this cytokine. IL-1β is an important marker for hepatic damage because in liver disease, 
IL-1β promotes the recruitment of inflammatory cells to the liver and activates hepatic 
stellate cells (HSCs), which contributes to fibrosis, an important characteristic of the 
progression from hepatic steatosis to steatohepatitis [28].   
 
5.4.5 OxLDL  
 
OxLDL is a mixture of lipoproteins with heterogeneous modifications such as oxidation 
of phospholipids, modification of apolipoprotein B (apoB) with malondialdehyde and 
aggregation of apoB [29]. These particles, in addition to being a functional biomarker for 
atherosclerosis, exhibit pro-inflammatory, immunogenic, apoptotic, and cytotoxic 
activities which can affect other organs and be a risk factor for other diseases, including 
NAFLD [30]. 
 
When LDL become oxidized, these particles display structures that are similar to 
pathogen-associated epitopes that increases their uptake by macrophages through SR-
A and CD36 [31]. This uptake has been widely documented for circulating 
macrophages, but also it has been reported that OxLDL is cleared from circulation by 
Kupffer cells, which are resident macrophages in the liver [29]. Specific membrane 
receptors for OxLDL have also been reported in HSCs and liver endothelial cells [4]. 
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In vitro studies show that OxLDL particles are further trapped in the lysosome 
compartment due to poor degradation, leading to presence of cholesterol crystals which 
can activate the inflammasome and induce the activation of NF-κB signaling [32,33]. 
Therefore, this OxLDL derived lysosomal lipid accumulation can been linked to hepatic 
inflammation, liver fibrosis and the progression of NASH [4,32].   
 
5.4.5 Gene Expression 
 
Diglyceride acyl transferase (DGAT) is the enzyme that catalyzes the final step in TG 
synthesis by adding a free fatty acid to sn-1,2- diacylglycerol [34,35]. The enzyme has 
two isoforms, DGAT1 and DGAT2, however, DGAT2 is the one primarily expressed in 
the liver [36]. Studies with animal models have suggested that this enzyme plays an 
important role in the development of hepatic steatosis [23]. Cheol et al. [36] showed in a 
rat model of diet-induced NAFLD, that targeting DGAT2 with anti-sense oligonucleotides 
not only improves hepatic steatosis, but also hepatic insulin signaling, and in vivo 
hepatic insulin sensitivity. The treated animals also showed decreased Sterol regulatory 
element-binding transcription factor 1 (SREBP1c)-mediated lipogenesis and increased 
hepatic fatty acid oxidation [36]. Similar results were obtained by Yu et al.[37] in a study 
done with	 high-fat diet-induced obese mice and ob/ob mice. The antisense 
oligonucleotide (ASO) reduced DGAT2 messenger ribonucleic acid (mRNA) 
concentration by more than 75% in the liver, which resulted in decreased DGAT activity 
in this tissue. The treatment did not cause significant changes in body weight, adiposity, 
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metabolic rate or insulin sensitivity; however, it caused a significant reduction in hepatic 
triglyceride content and improved hepatic steatosis in both models, caused not only by a 
decrease in triglyceride synthesis but also an increase in fatty acid oxidation [37]. In our 
study, the NANO group showed a significant reduction of hepatic gene expression of 
DGAT2 when compared to controls and this can explain the differences observed in 
steatosis score. Surprisingly, these data do not correlate with hepatic TG concentration, 
since there was no difference among groups. This could be because hepatic steatosis 
was not induced by a high fat diet, so the differences were not as abrupt to detect 
significant differences in TG accumulation. It is believed that in NAFLD progression, TG 
accumulation occurs initially as the “first hit” and the progression to more advanced 
stages of NAFLD, including inflammation and fibrosis (NASH), require a “second hit”. 
Dietary cholesterol could be this second hit, as it	 exacerbates hepatic macrophage 
infiltration, apoptosis, and oxidative stress. Therefore, cholesterol could be more related 
to NAFL progression to NASH than NADL induction [22,38,39]. In guinea pigs, however, 
a cholesterol challenge like the one we used for this study has shown to also induce the 
first hit, as it significantly increases the TG concentration in hepatic tissue [21,40]. 
 
As the experiment was designed with a cholesterol challenge, and the liver is a key 
organ for cholesterol metabolism [41], one of the main interests of this part of the study 
was the measurement of cholesterol metabolism-related genes. 
 
Intracellular cholesterol can be obtained through two pathways: uptake of LDL-C 
mediated by specific receptors (LDL-R) and by endogenous synthesis, mediated by the 
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mevalonate pathway, of which HMGCR is the rate-limiting enzyme [42]. An increased 
synthesis or a decreased uptake could explain the interesting findings in plasma 
lipoproteins (reported in the next chapter). Further, NAFLD has been associated with 
increased HMGCR expression and decreased phosphorylation [43]. In this study no 
differences in HMGCR mRNA expression was observed, however, the regulation of this 
enzyme is not only transcriptional, but also post-translational. High AMP:ATP ratio 
stimulates AMP-activated protein kinas,  which phosphorylates HMGR at a conserved 
serine in the active site, inhibiting HMGR activity [44].  
 
The inducible degrader of the LDL receptor (IDOL), also known as myosin regulatory 
light chain interacting protein (MYLIP) is an E3 ubiquitin ligase that mediates 
ubiquitination and degradation of the LDL-R limiting cholesterol uptake. IDOL is 
reported to be active in macrophages, adrenals, intestine and liver and play a role in the 
tissue response to changing cholesterol concentration [45,46]. Inhibition of IDOL could 
reduce plasma LDL-C by increasing LDL receptor density in the plasma membrane [46].  
 
Srebf2, the gene that encodes for SREBP-2 which is known to up-regulate genes 
involved in cholesterol biosynthesis and uptake [47] was higher in the PL group 
compared to both NANO and controls. As mentioned before, SREBP-2 activation can 
lead to an up-regulation of LDL-R, however, this was not observed in any of the groups. 
Further, no significant differences were observed in the cholesterol content in the PL 
group. It is important to note that the SREBP transcription factors are relatively weak 
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activators of gene expression alone, and these usually require the cooperation of other 
co- factors [48]. 
 
There was no difference in cluster of differentiation 36 (CD36) or cluster of 
differentiation 68 (CD68), CETP, Liver X receptor alpha (LXR-a) (encoded by the 
NR1H3 gene), SREBF1 or IL-β.  
5.5 Strengths and limitations 	
Among the strengths of this study is the use of guinea pigs as animal model. Guinea 
pigs not only resemble humans in lipoprotein metabolism, but also in the synthesis, 
storage, and catabolism of cholesterol in the liver [40]. This peculiarity is relevant when 
studying hepatic steatosis and NAFLD, because cholesterol accumulation in the 
hepatocytes is reported to be a key molecule in the transition to NASH [49]. Moreover, 
guinea pigs have shown to respond to dietary interventions, including carbohydrate 
restriction [21,50], dietary fiber [51] and most relevant for this study, lutein  
supplementation [7]. Powdered lutein has been shown to be protective against 
cholesterol-induced injury, which gave us a baseline to design this study adding the 
nanoemulsion.  
 
One limitation is that because this study design did not have a vehicle control group, it 
can be speculated that that the antioxidant effects of lutein could have acted 
synergistically with vitamin E in case this was released from TPGS. However, as 
previously mentioned, no vitamin E was found in plasma of the NANO group, which 
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suggest that the antioxidant effects observed are attributable to lutein only. Moreover 
there was no difference in hepatic OxLDL concentration between PL and NANO groups, 
suggesting that there was no synergistic effect between lutein and vitamin E in the 
NANO group.  
 
Another limitation would be the number of animals used in each group. There were 
many trends observed that may have reached significance if more statistical power was 
achieved [52].  
5.6 Conclusions 
The results for this part of the study show that a nanoemulsion of lutein is more effective 
that the same dose of powdered lutein in decreasing cholesterol-induced liver damage, 
specifically hepatic steatosis. However, no significant effect was observed in pro-
inflammatory cytokines. These results indicate that a higher concentration of lutein in 
the liver could give a greater protection against hepatic cholesterol accumulation but 
does not cause significant change in inflammation caused by a cholesterol challenge.  
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TABLES 
 
Table 5.1 List of designed primers for Cavia Porcellus for q-RT PCR 
 
Gene Protein 5'-Forward Primer-3' 5'-Reverse Primer-3' 
SREBF2 SREBP2 CTGAACGGGACAGCAGAGAG CAAACTGCAGCATCTCGTCG     
SREBF1 SREBP1 GGTGAGGTTTCCCGTTTTGC GAGGTGTCGGGACTTTGAGG 
  NR1H3 LXRα AAAGACCTCATGTCCTGCCG CAACCCGCAAAGTGACAGTG 
  MYLIP IDOL AGTCTGGGAACAGCATCGTG GTTTCGGTGATGGCTCGGTA 
  LDLR LDLR ACGTCAATGGCAGAGACAGG CCTGTAAGGCGGTTGACACT 
  IL-1β IL-1β TCCAGCGGATCTTCATTGCT TGCAGCTTGATCCCCTCATC 
  HMGCR HMGCR CAGTGTGACTGTTCCCACGA CAGTGTGACTGTTCCCACGA 
  GAPDH GAPDH GTCTGGCAAAGTGGATAT GGTAGAATCATACTGGAACA 
  DGAT2 DGAT2 TCCTACCGGGATGTCAACCT TTGTCTGGGTAGCGCACAAT 
  CETP CETP TGACGGGGGACAAGTTCAAG TCACGGAAGAACTGACCACG 
  CD68 CD68 CACCACCACCAATCATGGGA ACGGTGGTAGCATTTCCAGG 
  CD36 CD36 ATCTCTTTCGTGCAGCCCAA GCCAGGTTGAGGACTGTGAA 
  ACTB β-Actin CCTCTATGCCAACACAGTGC GTACTCCTGCTTGCTGATCC     
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Table 5.2 Concentration of hepatic total cholesterol (TC), free cholesterol (FC) and 
cholesterol esters (CE) of guinea pigs fed a hypercholesterolemic diet with no 
lutein (control) powdered lutein (PL) (3.5 mg/d) or nano-lutein (NANO) (3.5 mg/d) 
for 6 wk. 1 
 Control PL NANO 
TC (mg/g) 2.15±0.28a 2.05±0.58a 1.50±0.40b 
FC (mg/g) 0.50±0.09 0.40±0.21 0.38±0.12 
CE (mg/g) 1.63±0.26a 1.50±0.39ab 
 
1.18±0.42b 
 1 Values are means ± SD, n=8. Values in the same row with different superscripts are 
significantly different at P< 0.05.  
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TABLE 5.3. Concentration of hepatic inflammatory cytokines of male guinea pigs 
fed control, powdered lutein (PL) (3.5mg/d) or a nanoemulsion of lutein (NANO) 
(3.5 mg/d) diets for 6 wk 1. 
 Control PL NANO 
IFN-γ (ng/g) 155 ± 21 163 ± 53 155 ± 35 
IL-1β (ng/g) 45 ± 17a 32 ± 9b 26 ± 7b 
IL-6 (ng/g) 118 ± 35 98 ± 26 108 ± 17 
IL-10 (ng/g) 445 ± 40 483 ± 70 469 ± 98 
MCP-1 (ng/g) 
TNFα (ng/g) 
31 ± 5 
39 ± 4.0 
37 ± 10 
43 ± 13 
32 ± 14 
40 ± 14 
  
1 Values are means ± SD, n=8; Values in the same row with different superscripts are 
significantly different at P < 0.05 
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FIGURES 
 
Figure 5.1 Activity of liver enzymes Alanine Aminotransferase (ALT) and 
Aspartate Aminotransferase (AST) of guinea pigs fed a hypercholesterolemic diet 
with no lutein (control) powdered lutein (PL) (3.5 mg/d) or nano-lutein (NANO) (3.5 
mg/d). Values are mean ± SD, n=8. Bars without a common letter differ at P < 0.05. 
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Figure 5.2 Hepatic tissue histological evaluation of guinea pigs fed a 
hypercholesterolemic diet with no lutein (control, panel A) powdered lutein (PL, 
panel B) (3.5 mg/d) or nano-lutein (NANO, Panel C) (3.5 mg/d). Red arrows 
indicate lipid accumulation 
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Figure 5.3 Hepatic steatosis score of guinea pigs fed a hypercholesterolemic diet 
with no lutein (control) powdered lutein (PL) (3.5 mg/d) or nano-lutein (NANO) (3.5 
mg/d). Values are mean ± SD, n=8. Bars without a common letter differ at P < 0.05. 
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Figure 5.4 Concentrations of OxLDL in hepatic tissue of male guinea pigs fed a 
high cholesterol diet with no lutein (control), powdered lutein (PL) (3.5mg/d), or a 
nanoemulsion of lutein (NANO) (3.5mg/d) for 6 wks. Values are mean ± SD, n=8. 
Bars without a common letter differ at P < 0.05. 
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Figure 5.5 Hepatic relative Gene expression of male guinea pigs fed a high 
cholesterol diet with no lutein (control), powdered lutein (PL) (3.5mg/d), or a 
nanoemulsion of lutein (NANO) (3.5mg/d) for 6 wks. Values are mean ± SD, n=8. 
Bars without a common letter differ at P < 0.05. 
 	
	
 
 	
0	
0.5	
1	
1.5	
2	
2.5	
3	
3.5	
Hmgcr	 Ldlr	 Cetp	 Srebf2	 Nr1h3	 Mylip	 Cd36	 Dgat2	 Srebf1	 Il-1β	 Cd68	
Re
la
ti
ve
	E
xp
re
ss
io
n	
(2
-Δ
ΔC
t )	
Control	PL	NANO	a 
b 
ab 
b 
ab a 
	 105	
5.7 References 	
1. Sanchez-Valle, V.; Chavez-Tapia, N. C.; Uribe, M.; Mendez-Sanchez, N. Role of 
oxidative stress and molecular changes in liver fibrosis: a review. Curr. Med. Chem. 
2012, 19, 4850–4860. 
2. Li, S.; Tan, H.-Y.; Wang, N.; Zhang, Z.-J.; Lao, L.; Wong, C.-W.; Feng, Y. The Role of 
Oxidative Stress and Antioxidants in Liver Diseases. Int. J. Mol. Sci. 2015, 16, 26087–
124. 
3. Ye, P.; Cheah, I. K.; Halliwell, B. A high-fat and cholesterol diet causes fatty liver in 
guinea pigs. The role of iron and oxidative damage. Free Radic. Res. 2013, 47, 602–
613. 
4. Karadeniz, G.; Acikgoz, S.; Tekin, I. O.; Tascýlar, O.; Gun, B. D.; Cömert, M. 
Oxidized low-density-lipoprotein accumulation is associated with liver fibrosis in 
experimental cholestasis. Clinics (Sao Paulo). 2008, 63, 531–540. 
5. Bernal, C.; Martín-Pozuelo, G.; Lozano, A. B.; Sevilla, A.; García-Alonso, J.; 
Canovas, M.; Periago, M. J. Lipid biomarkers and metabolic effects of lycopene from 
tomato juice on liver of rats with induced hepatic steatosis. J. Nutr. Biochem. 2013, 24, 
1870–81. 
6. Yang, Y.; Pham, T. X.; Wegner, C. J.; Kim, B.; Ku, C. S.; Park, Y.-K.; Lee, J.-Y. 
Astaxanthin lowers plasma TAG concentrations and increases hepatic antioxidant gene 
expression in diet-induced obesity mice. Br. J. Nutr. 2014, 112, 1797–804. 
7. Kim, J. E.; Clark, R. M.; Park, Y.; Lee, J.; Fernandez, M. L. Lutein decreases 
oxidative stress and inflammation in liver and eyes of guinea pigs fed a 
hypercholesterolemic diet. Nutr. Res. Pract. 2012, 6, 113–9. 
8. Yilmaz, B.; Sahin, K.; Bilen, H.; Bahcecioglu, I. H.; Bilir, B.; Ashraf, S.; Halazun, K. J.; 
Kucuk, O. Carotenoids and non-alcoholic fatty liver disease. 2015, 4, 161–171. 
9. Yilmaz, B.; Sahin, K.; Bilen, H.; Bahcecioglu, I. H.; Bilir, B.; Ashraf, S.; Halazun, K. J.; 
Kucuk, O. Carotenoids and non-alcoholic fatty liver disease. HepatoBiliary Surg. Nutr. 
2015, 4, 161–171. 
10. Smith, P. K.; Krohn, R. I.; Hermanson, G. T.; Mallia,  a. K.; Gartner, F. H.; 
Provenzano, M. D.; Fujimoto, E. K.; Goeke, N. M.; Olson, B. J.; Klenk, D. C. 
Measurement of Protein Using Bicinchoninic Acid. Anal. Biochem. 1985, 150, 76–85. 
11. Carr, T. P.; Andresen, C. J.; Rudel, L. L. Enzymatic determination of triglyceride, 
free cholesterol, and total cholesterol in tissue lipid extracts. Clin. Biochem. 1993, 26, 
39–42. 
12. Aguilar, D.; deOgburn, R. C.; Volek, J. S.; Fernandez, M. L. Cholesterol-induced 
inflammation and macrophage accumulation in adipose tissue is reduced by a low 
carbohydrate diet in guinea pigs. Nutr. Res. Pract. 2014, 8, 625. 
13. Bruno, R. S.; Dugan, C. E.; Smyth, J. a; DiNatale, D. a; Koo, S. I. Green tea extract 
protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. J. 
Nutr. 2008, 138, 323–331. 
14. Li, Z.; Yang, S.; Lin, H.; Huang, J.; Watkins, P. A.; Moser, A. B.; DeSimone, C.; 
Song, X. Y.; Diehl, A. M. Probiotics and antibodies to TNF inhibit inflammatory activity 
and improve nonalcoholic fatty liver disease. Hepatology 2003, 37, 343–350. 
15. Kim, J. E.; Leite, J. O.; Smyth, J. A.; Clark, R. M.; Fernandez, M. L. A Lutein-
Enriched Diet Prevents Cholesterol Accumulation and Decreases Oxidized LDL and 
	 106	
Inflammatory Cytokines in the Aorta of guinea pigs. J. Nutr. 2011. 
16. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162, 156–
159. 
17. Giannini, E. G.; Testa, R.; Savarino, V. Liver enzyme alteration: A guide for 
clinicians. Cmaj 2005, 172, 367–379. 
18. Tolman, K. G.; Dalpiaz, A. S. Treatment of non-alcoholic fatty liver disease. Ther. 
Clin. Risk Manag. 2007, 3, 1153–1163. 
19. Ghouri, N.; Preiss, D.; Sattar, N. Liver enzymes, nonalcoholic fatty liver disease, and 
incident cardiovascular disease: A narrative review and clinical perspective of 
prospective data. Hepatology 2010, 52, 1156–1161. 
20. Sindhu, E. R.; Firdous, A. P.; Preethi, K. C.; Kuttan, R. Carotenoid lutein protects 
rats from paracetamol-, carbon tetrachloride- and ethanol-induced hepatic damage. J. 
Pharm. Pharmacol. 2010, 62, 1054–1060. 
21. DeOgburn, R.; Leite, J. O.; Ratliff, J.; Volek, J. S.; McGrane, M. M.; Fernandez, M. 
L. Effects of increased dietary cholesterol with carbohydrate restriction on hepatic lipid 
metabolism in guinea pigs. Comp. Med. 2012, 62, 109–115. 
22. Subramanian, S.; Goodspeed, L.; Wang, S.; Kim, J.; Zeng, L.; Ioannou, G. N.; 
Haigh, W. G.; Yeh, M. M.; Kowdley, K. V; O’Brien, K. D.; Pennathur, S.; Chait, A. 
Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL 
receptor-deficient mice. J. Lipid Res. 2011, 52, 1626–1635. 
23. Puri, P.; Baillie, R. a.; Wiest, M. M.; Mirshahi, F.; Choudhury, J.; Cheung, O.; 
Sargeant, C.; Contos, M. J.; Sanyal, A. J. A lipidomic analysis of nonalcoholic fatty liver 
disease. Hepatology 2007, 46, 1081–1090. 
24. Van Rooyen, D. M.; Larter, C. Z.; Haigh, W. G.; Yeh, M. M.; Ioannou, G.; Kuver, R.; 
Lee, S. P.; Teoh, N. C.; Farrell, G. C. Hepatic free cholesterol accumulates in obese, 
diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011, 141, 
1393–1403.e5. 
25. Ioannou, G. N.; Haigh, W. G.; Thorning, D.; Savard, C. Hepatic cholesterol crystals 
and crown-like structures distinguish NASH from simple steatosis. J. Lipid Res. 2013, 
54, 1326–34. 
26. Fabbrini, E.; Magkos, F. Hepatic Steatosis as a Marker of Metabolic Dysfunction. 
Nutrients 2015, 7, 4995–5019. 
27. Kijlstra, A.; Tian, Y.; Kelly, E. R.; Berendschot, T. T. J. M. Lutein: more than just a 
filter for blue light. Prog. Retin. Eye Res. 2012, 31, 303–15. 
28. Szabo, G.; Petrasek, J. Inflammasome activation and function in liver disease. Nat. 
Rev. Gastroenterol. Hepatol. 2015, 12, 387–400. 
29. Ishigaki, Y.; Oka, Y.; Katagiri, H. Circulating oxidized LDL: a biomarker and a 
pathogenic factor. Curr. Opin. Lipidol. 2009, 20, 363–369. 
30. Kontush, A.; Chapman, M. J. Functionally Defective High-Density Lipoprotein : A 
New Therapeutic Target at the Crossroads of Dyslipidemia , Inflammation , and 
Atherosclerosis. Pharmacol. Rev. 2006, 58, 342–374. 
31. Kunjathoor, V. V.; Febbraio, M.; Podrez, E. A.; Moore, K. J.; Andersson, L.; Koehn, 
S.; Rhee, J. S.; Silverstein, R.; Hoff, H. F.; Freeman, M. W. Scavenger receptors class 
A-I/II and CD36 are the principal receptors responsible for the uptake of modified low 
density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 2002, 277, 
	 107	
49982–49988. 
32. Bieghs, V.; Walenbergh, S. M. a; Hendrikx, T.; van Gorp, P. J.; Verheyen, F.; Olde 
Damink, S. W.; Masclee, A. a.; Koek, G. H.; Hofker, M. H.; Binder, C. J.; Shiri-Sverdlov, 
R. Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic 
inflammation. Liver Int. 2013, 33, 1056–1061. 
33. Ip, B. C.; Wang, X. D. Non-alcoholic steatohepatitis and hepatocellular carcinoma: 
Implications for lycopene intervention. Nutrients 2013, 6, 124–162. 
34. Dowman, J. K.; Tomlinson, J. W.; Newsome, P. N. Pathogenesis of non-alcoholic 
fatty liver disease. Qjm 2010, 103, 71–83. 
35. Purushotham, A.; Schug, T. T.; Xu, Q.; Surapureddi, S.; Guo, X.; Li, X. Hepatocyte-
Specific Deletion of SIRT1 Alters Fatty Acid Metabolism and Results in Hepatic 
Steatosis and Inflammation. Cell Metab. 2009, 9, 327–338. 
36. Cheol, S. C.; Savage, D. B.; Kulkarni, A.; Xing, X. Y.; Liu, Z. X.; Morino, K.; Kim, S.; 
Distefano, A.; Samuel, V. T.; Neschen, S.; Zhang, D.; Wang, A.; Zhang, X. M.; Kahn, 
M.; Cline, G. W.; Pandey, S. K.; Geisler, J. G.; Bhanot, S.; Monia, B. P.; Shulman, G. I. 
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with 
antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin 
resistance. J. Biol. Chem. 2007, 282, 22678–22688. 
37. Yu, X. X.; Murray, S. F.; Pandey, S. K.; Booten, S. L.; Bao, D.; Song, X. Z.; Kelly, S.; 
Chen, S.; McKay, R.; Monia, B. P.; Bhanot, S. Antisense oligonucleotide reduction of 
DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. 
Hepatology 2005, 42, 362–371. 
38. Wouters, K.; van Gorp, P. J.; Bieghs, V.; Gijbels, M. J.; Duimel, H.; L??tjohann, D.; 
Kerksiek, A.; van Kruchten, R.; Maeda, N.; Staels, B.; van Bilsen, M.; Shiri-Sverdlov, R.; 
Hofker, M. H. Dietary cholesterol, rather than liver steatosis, leads to hepatic 
inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. 
Hepatology 2008, 48, 474–486. 
39. Wouters, K.; Bilsen, M. Van; Gorp, P. J. Van; Bieghs, V.; Lütjohann, D.; Kerksiek, 
A.; Staels, B.; Hofker, M. H.; Shiri-Sverdlov, R. Intrahepatic cholesterol influences 
progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic 
mice. FEBS Lett. 2010, 584, 1001–1005. 
40. DeOgburn, R.; Murillo, A. G.; Fernandez, M. L. Guinea pigs as models for 
investigating non-alcoholic fatty liver disease. Integr. Food, Nutr. Metab. 2016, 3, 309–
313. 
41. Tall, A. R.; Yvan-charvet, L. Cholesterol , inflammation and innate immunity. Nat. 
Publ. Gr. 2015, 15, 104–116. 
42. Brown, A. J.; Jessup, W. Oxysterols and atherosclerosis. Atherosclerosis 1999, 142, 
1–28. 
43. Min, H.; Ph, D.; Kapoor, A.; Fuchs, M.; Mirshahi, F.; Sc, M.; Zhou, H.; Maher, J.; 
Kellum, J.; Warnick, R.; Contos, M. J.; Sanyal, A. J. Increased hepatic synthesis and 
dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic 
fatty liver disease. Cell Metab. 2013, 15, 665–674. 
44. Burg, J. S.; Espenshade, P. J. Regulation of HMG-CoA reductase in mammals and 
yeast. Prog. Lipid Res. 2011, 50, 403–410. 
45. Ramasamy, I. Recent advances in physiological lipoprotein metabolism. Chim 
Chem Lab Med 2014, 52, 1695–1727. 
	 108	
46. Scotti, E.; Hong, C.; Yoshinaga, Y.; Tu, Y.; Hu, Y.; Zelcer, N.; Boyadjian, R.; Jong, 
P. J. De; Young, S. G.; Fong, L. G.; Tontonoz, P. Targeted Disruption of the Idol Gene 
Alters Cellular Regulation of the Low-Density Lipoprotein Receptor by Sterols and Liver 
X Receptor Agonists Targeted Disruption of the Idol Gene Alters Cellular Regulation of 
the Low-Density Lipoprotein Receptor by Ste. 2011, 31, 1885–1893. 
47. Wong, J.; Quinn, C. M. M.; Brown, A. J. J. SREBP-2 positively regulates 
transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for 
LXR. Biochem. J. 2006, 400, 485–491. 
48. Sharpe, L.; Brown, A. Controlling cholesterol synthesis beyond 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGCR). J. Biochem. 2013. 
49. Kerr, T.; Davidson, N. Cholesterol and NAFLD: Renewed focus on an old villain. 
Hepatology 2012, 29, 997–1003. 
50. Torres-Gonzalez, M.; Shrestha, S.; Sharman, M.; Freake, H. C.; Volek, J. S.; 
Fernandez, M. L. Carbohydrate restriction alters hepatic cholesterol metabolism in 
guinea pigs fed a hypercholesterolemic diet. J. Nutr. 2007, 137, 2219–2223. 
51. Fernandez, M. L.; Ruiz, L. R.; Conde,  a K.; Sun, D. M.; Erickson, S. K.; McNamara, 
D. J. Psyllium reduces plasma LDL in guinea pigs by altering hepatic cholesterol 
homeostasis. J. Lipid Res. 1995, 36, 1128–1138. 
52. Charan, J.; Kantharia, N. How to calculate sample size in animal studies? J. 
Pharmacol. Pharmacother. 2013, 4, 303. 
  
	 109	
 
 
 
 
 
 
Chapter 6 
The effects of a nanoemulsion of lutein on plasma 
lipoproteins and adipose tissue inflammation 
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6.1 Background 
 
 
The insolubility of cholesterol and TG in plasma requires that they are transported in 
lipoproteins, which are distinguished from each other by size, density, electrophoretic 
mobility, composition and function [1]. Understanding lipoprotein metabolism has 
important clinical implications because altered lipoprotein profiles are considered a key 
risk factor for numerous chronic diseases such as CVD, MetS,  NAFLD and T2DM, 
among others [2–5]. 
 
Early work suggested that dietary cholesterol increased plasma total cholesterol 
concentrations in humans [6]. However, it is now well established that the response to 
dietary cholesterol varies among individuals [7]. Besides, not only may dietary 
cholesterol raise circulating cholesterol concentrations, but also fatty acid or 
carbohydrate-induced cholesterol biosynthesis can contribute to this phenomenon [8,9] 
 
The guinea pig has been shown to be a suitable model for investigating lipoprotein 
profile changes mediated by dietary factors, including cholesterol challenges [9–11]. 
The great advantage of these animals is that their cholesterol metabolism is the closest 
to the human situation in small laboratory animals [12] which makes them ideal models 
to understand molecular mechanisms and alterations of metabolic pathways induced by 
dietary interventions [10,13] 
White adipose tissue has traditionally been considered as an inert tissue mainly devoted 
to fuel storage in the form TG, however, it is now recognized that this tissue has very 
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important roles in homeostasis, energy balance, glucose metabolism, immunity and 
inflammation [14–16].  
 
In addition to adipocytes, the adipose tissue includes nerves, immune cells and 
connective tissue. This complexity not only affects structure but also functionality of the 
adipose tissue. Nowadays adipose tissue is considered a very active endocrine organ 
which secrets several key hormones, such as leptin and adiponectin, but also many 
other bioactive substances called adipokines [17]. These adipokines include pro- 
inflammatory cytokines such as TNFα, IL-6, and MCP-1[17]. 
 
An important feature of inflammation is infiltration of immune cells such as neutrophils, 
eosinophils and macrophages. Macrophage infiltration in adipose tissue has recently 
been described in obese conditions in rodents and humans [18]. This infiltration alters 
the production and release of pro-inflammatory cytokines that can trigger insulin 
resistance and the hepatic production of acute inflammatory molecules like Serum 
Amyloid A and C-reactive protein, creating a loop of systemic inflammation [19]. 
 
Dietary cholesterol has been reported to exacerbate adipose tissue inflammation in 
several animal models [19,20], suggesting that high dietary cholesterol can lead to 
adipocyte dysfunction and contribute to systemic inflammation [21].  
 
In addition to their scavenging function toward reactive oxygen species (ROS), there is 
growing evidence that carotenoids may also act via more indirect pathways. This 
	 112	
indirect route may include interactions with cellular signaling cascades, such as NF-κB, 
MAPK, or c (Nrf2) [22].  
 
It was our hypothesis for this part of the study that a nanoemulsion of lutein would be 
more effective than the same dose of regular powdered lutein in ameliorating 
cholesterol induced dyslipidemia and inflammation in the adipose tissue. 
 
6.2 Materials and Methods 
 
6.2.1 Fasting Plasma Lipids: TC, HDL HDL-C, and TG, were measured using a Cobas 
C 111 analyzer (Roche Diagnostics, Indianapolis, IN). This instrument uses direct 
enzymatic reactions and photometric detection. LDL-C was calculated using the 
Friedewald equation [23]. 
 
6.2.2 Lipoprotein Subfractions and Size: NMR spectroscopy was performed on a 400-
MHz NMR analyzer (Bruker BioSpin) as previously described [9]. This method provides 
the concentrations of large, medium and small VLDL, LDL and HDL particles [24,25]. 
 
6.2.3 OxLDL: Plasma OxLDLs were measured with a specific guinea pig OxLDL ELISA 
kit (MyBioSource, Inc, San Diego California) according to manufacturers’ instructions. 
 
6.2.4 Inflammatory Cytokine Concentration in the adipose tissue:   
Tissue total protein was extracted using RIPA buffer and total protein concentration of 
the lysates were determined using the BCA Protein Assay Kit (Cell Signaling 
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Technologies Inc, Beverly, MA) [26]. Using the same concentration of protein for all 
samples, the following cytokines were measured using Luminex technology (Luminex 
MAGPIX System, Austin, TX) with the MILLIPLEX MAP Rat Cytokine Immunoassay kit 
(Millipore corporation, Charles, MO, USA): IL-1β, IL-6, IL-10, IFN-γ,  MCP-1, and TNFα, 
as previously described [27]. 
 
6.2.5 Histologic evaluation 
Small pieces of adipose tissue samples were immersed in 10% buffered formalin. 
Formalin-fixed adipose were paraffin embedded and 3–5 µm sections were stained with 
hematoxylin and eosin. A veterinary pathologist blinded to the treatments performed 
histologic evaluation on two separate occasions. A low magnification screen of the 
entire tissue was assessed for evidence of abnormality and crown-like structures and 
signs of inflammation were quantified in 10 fields at 200X. 
 
6.2.6 Statistical Analysis: 
Differences between groups were analyzed by one-way ANOVA and Fisher’s LSD post 
hoc analysis. Pearson correlations were calculated between plasma lutein and plasma 
lipoproteins. P < 0.05 was considered to be significant. All analyses were conducted on 
SPSS for Windows, Version 20 (IBM Corp.)  
6.3 Results 
 
6.3.1 Plasma Lipids, Lipoprotein Size and Subfractions 
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The NANO group showed significantly higher concentrations of plasma TC, LDL-C and 
HDL-C compared to the other treatments(P < 0.001) (Figure 6.1).  
 
Total VLDL and all its subfractions (large, medium and small) were highest in the NANO 
group (P < 0.05) (Table 6.1). Similarly, total LDL, IDL, large and small LDL were highest 
in the NANO group. In the case of HDL, the total HDL was higher in the NANO 
compared to the other groups in agreement with highest concentrations of small HDL. In 
contrast, the large HDL was also lowest in the NANO group (Table 6.1).  Significant 
correlations were found between plasma lutein and LDL-C (Fig 6.2, Panel A), HDL-C 
(Fig 6.2, Panel B), number of LDL particles (Fig 6.2, Panel C) and number of HDL 
particles (Fig 6.2, Panel D). 
 
6.3.3 Oxidative stress markers in plasma 
Guinea pigs from the NANO group showed a significantly lower oxidation in LDL 
particles in plasma (2.8±0.95 ng/mL) when compared to PL (6.1±4.4 ng/mL) or control 
(7.9±2.1ng/mL) (Figure 6.3). 
 
6.3.3 Cholesterol Accumulation and Inflammatory Markers in Adipose Tissue 
TC and FC concentrations were higher in the NANO group compared to the other 
groups (P < 0.05), while EC concentrations were higher in the NANO and control 
groups, when compared to the PL group (Table 6.2). 
 
	 115	
The inflammatory markers IFN-γ and MCP-1 were higher in the NANO group compared 
to both PL and control groups; Similarly, IL-10, an anti-inflammatory cytokine, was also 
higher in the NANO group compared to other treatments (Table 6.3). Histologically, 
there was no differences in the adipose tissue morphology or in the presence of crown-
like structures among groups. 
6.4 Discussion 
 
6.4.1 Plasma lipids and Lipopoproteins 
The observed changes in plasma lipoproteins are unexpected and undesirable because 
they represent a more atherogenic lipoprotein profile [28].  An increase in LDL-C is 
traditionally seen as an independent atherogenic marker, however, if HDL-C is also 
increased, and the LDL/HDL ratio is unaltered there is no change in cardiovascular risk 
[3]. In the present study, LDL-C in the NANO group was three fold higher than the 
control group; while HDL-C was only near to double the concentration of the control 
group, therefore the LDL/HDL ratio with the nanoemulsion of lutein (3.3) was higher 
when compared to controls (2.5), indicating a shift towards an atherosclerotic risk. A 
similar outcome was observed for the TC/HDL ratio, also known as the Castelli ratio [3] 
since the TC concentration in the NANO group was 2.7 times higher than the TC 
concentration in the control group (Figure 6.1) yielding Castelli ratios of 3.7 in the 
control group and 4.4 in the case of the NANO group.  
 
As previously stated, given the lipophilic nature of carotenoids, they are transported in 
lipoproteins once they are absorbed in the gut [29]. Lutein, specifically, is packed into 
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chylomicrons and transported via the lymphatic system to the liver, where it can be 
stored or further packed into VLDL to be transported throughout the body [30].  In 
addition to the chylomicron pathway, recent studies have shown that lutein could be 
incorporated into HDL directly from the basolateral membrane of the enterocyte via an 
ABCA1/ApoA1 pathway [31].  Independently of the absorption pathway, an important 
characteristic of xanthophylls is that they are mainly transported in HDL particles [32–
35], whereas carotenes are preferably carried in LDL particles [34,36]. In the Los 
Angeles Atherosclerosis Study, it was shown in a cohort of 269 adult women and 304 
men that plasma lutein concentration was positively correlated to HDL-C concentration 
[37].  Blesso et al. [35], showed that egg (a natural source of high bioavailable lutein) 
consumption in patients with metabolic syndrome increased not only the concentration 
but the size of HDL particles, which also had an increase of carotenoid content [35] Due 
to greater surface area, larger HDL particles are more suitable for xanthophyll transport 
[35]. These larger HDL particles are also hypothesized to be more anti-atherogenic 
[35,38]. 
 
It is important to note that lutein is also carried by LDL, and some authors have 
suggested that an increase in lutein concentration in the body would lead to an increase 
in both lipoproteins. As reported by Renzi et al.[34] and Waters et al. [39] circulating 
levels of xanthophylls lutein and zeaxanthin are positively correlated with both serum 
HDL and LDL fractions [34,39]. 
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The same correlations were found in the present study, as lutein concentration in 
plasma is positively correlated not only with LDL and HDL cholesterol concentration, but 
also with the number of LDL and HDL particles. This situation could explain, partially, 
the higher concentrations of TC, LDL-C and HDL-C as well as of all lipoprotein 
subfractions.  However, there was no difference between the powdered lutein and the 
control group, which suggests that a component of the nanoemulsion played a role in 
the alteration of the lipid profile seen in the NANO group. It could also be possible that 
the MCT oil used to emulsify the lutein for the NANO group had a negative impact on 
lipoprotein metabolism. It has been reported that a similar hypercholesterolemic effect 
was observed in humans.  In a study with a double-blind, randomized, crossover 
design, 17 healthy young men were given 70 g of MCT oil (66% 8:0 and 34% 10:0) for 
12 days resulting in 11% higher plasma TC, 12% higher LDL-C, 32% higher VLDL 
cholesterol and 22% higher plasma TG when compared to high-oleic sunflower oil 
(89.4% 18:1) [40]. Similar findings were reported by Carter et al. [41], who compared the 
lipid effects of a diet supplemented with either MCTs, palm oil, or high oleic acid 
sunflower oil in nine middle-aged men with mild hypercholesterolemia. Although palm oil 
is known to have hypercholesterolemic effects and MCT are popularly believed to be 
neutral, in Carter’s study MCT oil increased the concentration of TC and LDL-C in a 
similar fashion to palm oil. Both palm and MCT oils resulted in significantly higher 
concentrations of TC and LDL-C when compared to oleic acid [41].  What makes MCT 
attractive is that they bypass the CM pathway and are sent directly to the liver via the 
portal vein where they can be rapidly catabolized as opposed to be stored. It is 
hypothesized, however, that the acetyl CoA end products of those fatty acids (8:0 and 
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10:0) oxidation are resynthesized into long-chain fatty acids [8]. The increased de novo 
lipid synthesis would lead to an increase in hepatic TG production and thereby to VLDL 
secretion, which can explain the elevation in both TC and TG in plasma of animal and 
human studies [40,41]. 
 
This hypothesis could explain why, although the PL group had significantly more lutein 
than the control group in plasma and liver, the shift towards an atherogenic lipoprotein 
profile was only observed in the NANO group. However, the dose used for this 
Tholstrup’s trial was 70 grams of MCT, which is substantially higher than the one used 
in the nanoemulsion. However, there are not enough data about how much MCT is 
needed to have this effect in plasma lipoproteins.   
 
The MCT oil could have also affected cholesterol absorption. Based on the results 
presented in the previous chapter, it is possible that the differences observed in plasma 
lipoproteins are not derived from an increased synthesis of endogenous cholesterol or 
decreased degradation of LDL in the NANO group. We can speculate that the increased 
cholesterol concentration in plasma lipoproteins is derived from dietary cholesterol that 
could have been absorbed more efficiently with the addition of MCT oil to the diet. This 
assumption is supported by a study done with C57L mice, where Wang et al. showed 
that dietary cholesterol is absorbed differently when different oils are used as vehicle. 
Wang reported that with MCT oil, cholesterol showed a higher percentage of absorption 
when compared to other vehicles such as corn and soybean oil, but less absorption 
when compared to olive oil or safflower oil [42]. 
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Alternatively, it could be possible that the fact that lutein was given in a nanoemulsion 
could have caused the detrimental changes, because an important consideration of 
nano-technology is that materials in the nano-scale behave differently from the same 
materials in bulk, which means that a change in size could have harmful effects in 
biological systems with a higher potential to generate some sort of toxicity or undesired 
effect [43]. 
 
Overall, the results suggest that the use of this particular nanoemulsion formulation may 
be detrimental in terms of cardiovascular risk independently of lutein concentration. 
Further studies with the nano-formulation used in the present study are needed to 
evaluate the effects of the different components of the nanoemulsion on lipoprotein 
metabolism.  
 
 
6.4.2 OxLDL  
 
An important risk factor for atherosclerosis is the accumulation of cholesterol-rich, apoB-
containing lipoproteins like LDL in the intima of arterial walls [44–46]. These 
sequestered lipoproteins are prone to be modified via oxidation, enzymatic and non-
enzymatic cleavage or aggregation, which make these particles pro-inflammatory and 
pro-atherogenic [45]. For example, OxLDL are accumulated in macrophages 
transforming them into the cholesterol-rich foam cells which along with apoptotic cells, 
debris and cholesterol crystals form a necrotic core and cause luminal narrowing of 
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arteries [45–47]. For this reason, circulating OxLDL in plasma is a good predictor of 
atherosclerosis and associated risk factors, and many studies have found strong 
correlations between plasma OxLDL with the disease progression [48]. 
 
In this study, despite the fact that the NANO group had a considerable elevation of LDL-
C and smaller LDL particles, we found the lowest concentration of OxLDL particles in 
plasma. These results point to a protective effect of lutein on the oxidation of LDL in 
spite of the higher concentrations of this lipoprotein.  Similar effects of lutein have been 
reported previously. Kim et al. [27] conducted a study with cholesterol challenged 
guinea pigs (0.25 g cholesterol/100 g) randomly assigned to a non-purified diet or a diet 
with a supplementation of 3 mg per day of lutein for 12 weeks. While plasma LDL 
cholesterol did not differ between groups, OxLDL concentrations were decreased in 
both plasma and aorta of supplemented guinea pigs [27].  
 
Dwyer et al. [37] studied the effects of lutein supplementation with apoE knockout mice, 
which develop severe atherosclerosis morphologically similar to the human situation. In 
this experiment, 10 mice were assigned to a chow diet (control) or a chow diet with 
added lutein (0.2% by weight) starting at 8 weeks of age. The results of this experiment 
show that lutein supplementation decreased LDL oxidation in a dose-dependent manner 
[37]. Similarly, in a dietary intervention with thirty-five women with metabolic syndrome 
and high plasma LDL following a Mediterranean-style low-glycemic-load diet for 12 
weeks, the changes in plasma oxLDL concentration were inversely correlated with 
plasma lutein [49]. It is believed that this effectiveness has to do with lutein-rich HDL 
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particles, which could be more effective in preventing the oxidation of LDL particles, 
given the fact that this polar carotenoid is located in the surface of lipoproteins. [50] 
 
6.4.3 Cholesterol accumulation in adipose tissue  
Previous studies have shown that dietary cholesterol challenges induce cholesterol 
accumulation in adipose tissue in guinea pigs [51] and that this cholesterol 
accumulation increases macrophage infiltration and concentrations of inflammatory 
cytokines [21]. Given the anti-oxidant and anti-inflammatory properties of lutein, and the 
fact that the adipose tissue is a site of carotenoid storage [52] we hypothesized that a 
higher concentration of this carotenoid in the adipose tissue would have protective 
effects against cholesterol-induced damage.  
 
In this study, however, despite showing a higher concentration of lutein than the control 
group, the NANO group also had a higher concentration of FC when compared to 
controls and of TC and CE when compared to PL. FC is toxic to cells and induces 
inflammatory responses such as activation of the inflammasome [45]. In cultured cells, 
excess cellular FC is transported to the plasma membrane where it induces a number of 
cellular responses, including cholesterol crystallization and cell death [53]. These results 
can be explained by the fact that although adipose tissue stores most of the free 
cholesterol in the body, cholesterol synthesis is low when compared to other cell types, 
which means that the cholesterol found in this tissue comes from plasma lipoproteins 
[54]. In this study, the lipoprotein profile of the NANO group was significantly altered, 
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and these circulating lipoproteins could have negatively influenced the cholesterol 
content of the adipocytes. 
 
6.4.4 inflammatory markers in the adipose tissue   
Consequent to the increased concentration of FC, we also found a higher concentration 
of pro-inflammatory cytokines IFNγ and MCP-1 in the adipose tissue of the NANO group 
when compared to other treatments. Interestingly, IL-10, a known anti-inflammatory 
cytokine [55] was also higher in this group.  
 
A possible explanation for these unexpected results in the adipose tissue is that 
carotenoids, besides antioxidants, are also reported to act as prooxidants under high 
oxygen tension, high carotenoid concentration and imbalanced intracellular redox status 
[56]. Under high oxidative stress, while scavenging ROS, carotenoids get oxidized and 
generate highly reactive aldehydes that have been linked to oxidative stress similar to 
that caused by lipid peroxidation products in vitro and in vivo [57]. However, there is a 
lack of data reporting a plasma or tissue lutein concentration linked to these detrimental 
effects, and in animal studies, dosages of lutein significantly higher than the one used 
for this study have not reported adverse effects or indication of lutein toxicity [58]. 
 
It is more likely that the detrimental changes observed in the NANO group are caused 
by the altered lipoprotein profile and not by lutein per se.  Hypercholesterolemia has 
been shown to cause adipose tissue dysfunction in obese and not obese subjects [51] 
and in the present study, the plasma concentrations of both TC and LDL-C were 
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probably too high to be counteracted by the dose of lutein consumed by the guinea pigs 
and this could be the cause of adipose tissue increased cholesterol accumulation and 
inflammatory response in the NANO group. Interestingly, no differences were observed 
in the histological evaluation of the adipose tissue among groups. 
6.5 Strengths and limitations 
 
A strength of this study is the use of the guinea pig as the animal model, because these 
animals mimic human hepatic cholesterol and lipoprotein metabolism [10,13].  
The main limitation of this part of the study is, once again, the lack of an empty vehicle 
control. In this case, having a group eating chow with a nanoemulsion without lutein 
could have tested the speculation that a low dose of MCT oil consumed by the NANO 
GROUP could have caused such significant changes in the lipid profile.  
 
Also, as previously stated, the detrimental changes observed in the adipose tissue are 
most likely caused by the detrimental changes in the lipoprotein profile, which interfered 
with the potential of lutein in ameliorating the inflammatory responses in this tissue 
induced by a cholesterol challenge. It would have been interesting to observe if there 
were changes in the mRNA expression of genes of interest in the adipose tissue, 
however, the RNA extracted for this essay was degraded and the assays could not be 
performed.  
 
As mentioned before, OxLDL is a good predictor of atherosclerosis [59], and we found 
lower concentrations of this modified lipoprotein both in plasma and liver, however, 
there are no data regarding the aortas of the guinea pigs or any other atherosclerosis 
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risk markers. This is because hypercholesterolemic guinea pigs show NAFLD features 
before developing atherosclerosis, which usually takes 12 weeks [27,60]. A longer study 
design could have added valuable data about lutein and atherosclerosis risks to this 
project. 
6.6 Conclusions 
 
Based on our results, it can be concluded that the formulation of the nanoemulsion of 
lutein used in this study caused detrimental changes in lipoprotein metabolism and 
inflammatory markers in the adipose tissue of guinea pigs. We cannot be certain which 
component of the nanoemulsion caused so much damage in the NANO group. 
However, it seems that this particular nanoemulsion, although increasing the 
bioavailability of lutein as discussed in previous chapters, exacerbates the negative 
impact of a cholesterol challenge in the organism. Further studies are needed to 
understand the mechanisms underlying this observed phenomenon and until then, the 
use of this specific nanoemulsion is not recommended for humans. 
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TABLES 
 
Table 6.1 Lipoprotein subfractions of male guinea pigs fed control, powdered 
lutein (PL) (3.5 mg/d), or lutein nanoemulsion (NANO) (3.5 mg/d) for 6 wk1. 
  Control PL NANO 
Total VLDL 
(nmol/L) 44.7±14.7a 56.8±27.9a 125±37.9b 
Large VLDL  
(60-100 nm) 1.0±0.9a 1.6±0.9a 4.1±1.9b 
Medium VLDL  
(40-60 nm) 11±4.6a 19±9.8a 38±14.5b 
Small VLDL  
(30-40 nm) 32±10a 36±18a 83±23b 
Total LDL  
(nmol/L) 506±116a 620±199a 1,190±246b 
 
Large LDL  
(23-30 nm) 
 
109±28a 102±33a 155±61b 
Small LDL  
(20.5-23 nm) 341±103a 424±142a 859±178b 
 
Very small LDL  
(18-20.5) 
274±20a 341±31a 685±41b 
Total HDL  
(µmol/L) 1.4±0.7a 2.0±1.0a 3.6±1.5b 
Large HDL  
(10-13 nm) 0.15±0.15a 0.17±0.07a 0.03±0.05b 
 
Medium HDL  
(8.2-10 nm) 
 
0.14±0.18 0.24±0.13 0.11±0.18 
Small HDL   
(7.3-8.2 nm) 1.2±0.7a 1.6±0.9a 3.5±1.5b 
1 Values are means ± SD, n=8; Means in the same row without a common letter differ at P < 
0.05 
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TABLE 6.2. Concentration of adipose tissue TC, FC and CE of guinea pigs fed a 
hypercholesterolemic diet with no lutein (control) powdered lutein (PL) (3.5 mg/d) 
or nano-lutein (NANO) (3.5 mg/d). 1 
 Control PL NANO 
Total Cholesterol (mg/g) 10.16±1.51ab 9.20±0.78a 11.52±2.50b 
Free Cholesterol (mg/g) 5.10±0.30a 5.51±0.80ab 6.30±1.30b 
Cholesterol Esters (mg/g) 5.03±1.50b 3.68±0.93a 5.13±1.58b 
 
1 Values are means ± SD, n=8. Values in the same row with different superscripts are 
significantly different at P< 0.05.  
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Table 6.3 Concentration of inflammatory cytokines in adipose tissue of  male 
guinea pigs fed control, powdered lutein (PL), or nanoemulsion (NANO) diets for 
6 wk 1. 
 Control PL NANO 
IFN-γ (ng/g) 76 ± 12a 70 ± 10a 120 ± 22b 
IL-1β (ng/g) 103 ± 24 111 ± 30 122 ± 23 
IL-6  (ng/g) 39 ± 3 38 ± 4 39 ± 11 
IL-10  (ng/g) 106 ± 25a 113 ± 35a 155 ± 31b 
MCP-1 (ng/g) 19 ± 2a 20 ± 2a 40 ± 21b 
TNFα (ng/g) 18 ± 3 18 ± 2 22 ± 2 
 1 Values are means ± SD, n=8. Values in the same row with different superscripts are 
significantly different at P < 0.05 
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FIGURES 
 
Figure 6.1 Lipid profile: triglycerides (TG), total cholesterol (TC), high density 
lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) 
concentrations of male guinea pigs fed the control, powdered lutein (PL) and 
lutein nanoemulsion (NANO) diets (3.5mg/d) for 6 wks. Values are mean ± SD, n=8 
per group. Bars without a common letter differ at P < 0.05. 
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Figure 6.2 Pearson correlations between plasma lutein and LDL-C concentration 
(Panel A), HDL-C concentration (Panel B), number of LDL particles (Panel C), and 
number of HDL particles (Panel D) of guinea pigs fed the control, powdered lutein 
(PL) and lutein nanoemulsion (NANO) diets. 
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Figure 6.3 Concentrations of OxLDL in plasma of male guinea pigs fed a high 
cholesterol diet with no lutein (control), powdered lutein (PL) (3.5mg/d), or a 
nanoemulsion of lutein (NANO) (3.5mg/d) for 6 wks. Values are mean ± SD, n=8. 
Bars without a common letter differ at P < 0.05. 
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7.1 Conclusions 
 
This project demonstrated that a nanoemulsion of lutein made with MCT oil  and  TPGS 
posses the characteristics of a stable and monodisperse preparation, which suggests 
that these ingredients are suitable for the successful nanoencapsulation of lipophilic 
nutraceuticals.  
 
Most importantly, we confirmed our hypothesis that this nanoemulsion of lutein would be 
more bioavailable than the same dose of powdered lutein, as a higher concentration 
was found in both plasma and liver of the guinea pigs from the NANO group, when 
compared to both controls and PL, and in other tissues like adipose tissue and eyes, 
when compared to controls. These results suggest that nanotechnology is a good 
approach to overcome the challenges that bioactive components, in this specific case, 
lutein, have to exert their biological activity: low intake and poor bioavailability.  
 
Moreover, the higher concentration of lutein were shown to be more effective in 
protecting the hepatic tissue against cholesterol-induced damage; as the NANO group 
showed lower liver weight, concentration of both TC and CE, ALT, steatosis score and 
DGAT2 mRNA expression. However powdered lutein also exhibited these protective 
effects, as there were no differences in hepatic oxidized OxLDL despite the different in 
tissue concentration. 
 
However, an unexpected result was observed in the NANO group as these animals 
showed significantly higher concentrations of all lipoproteins, which means a shift 
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towards an atherogenic lipid profile. This negative result had a detrimental impact on the 
adipose tissue, as seen in a higher expression of pro inflammatory cytokines and FC. 
These results suggest that lutein’s antioxidant and anti-inflammatory effects may not be 
sufficient in cases of severe hypercholesterolemia.  
 
Overall, although the use of this particular nanoemulsion formulation may be beneficial 
in terms of increasing the concentrations of lutein in plasma and target tissues and 
exerting better hepato-protective bioactivity, it may be detrimental to the whole system, 
inducing an atherogenic lipid profile and aggravating the systemic inflammation caused 
by a cholesterol challenge.  
 
7.2 Future directions 
 
The importance of conducting this project lies in the attempt to surmount the knowledge 
gap that exists in using nanotechnology to improve bioavailability and efficacy of lutein. 
However, there are many questions that remained unanswered by the completion of the 
study.  
 
The results presented in this dissertation showed that the nanoemulsion increased the 
bioavailability of lutein, but it was not elucidated how. The stability and behavior of the 
nano preparation in the digestive tract has yet to be tested with an in vitro digestion. 
Intestinal cell culture studies could also provide valuable information about the fate of 
the nanoemulsion particles in the intestine. In addition, the hypothesis that TPGS 
inhibits MDR1 in the enterocyte has yet to be confirmed. 
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An important limitation in this project was the lack of an empty vehicle control. A similar 
study should be conducted using a nanoemulsion without lutein to evaluate the 
individual or synergistic effects of the nanoemulsion ingredients, specifically TPGS and 
MCT oil in the systemic responses observed in this project. Another control that could 
be tested could be a group of guinea pigs receiving the same ingredients of the nano 
preparation but without being nanoemulsified. This will help us evaluate the differences 
in the effects that the ingredients have as a nano-delivery system versus the same 
materials in bulk.  
In addition, the preparation used is not the only way to make nanoemulsions. Several 
surfactants and carrier oils can be used and tested in order to find the most efficient 
formulation that would increase the lutein concentration in target tissues without having 
the detrimental effects observed in this study.  
 
In future studies, the effects of a nanoemulsion of lutein should be tested in several 
target tissues where lutein accumulates, such as the brain, lungs and spleen. In 
addition, the incorporation of lutein into the diet at the beginning of the study only gives 
us information about the potential of this carotenoid as a preventive agent, not as 
treatment. A study where lutein is added to the diet 6 weeks after the cholesterol 
challenge, to insure that damage is achieved could show the potential of lutein as a 
therapeutic, not only preventive, nutraceutical.  
It could also be interesting to compare the efficacy of absorption of lutein between a 
nanoemulsion and egg yolks, because this dietary source is known to have the best 
natural composition (fat, free lutein, digestible matrix) to achieve maximum 
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bioaccesibility of this carotenoid. Finally, a study with humans is imperative to see if the 
effects observed in this study are reproducible and of clinical importance.  
 
Although a promising alternative, the use of nanotechnology in oral formulations for 
nutraceuticals should be tested with other parameters of safety and efficacy in order to 
know if it is safe to move forward to perform clinical trials with oral nano formulations of 
lutein. So far, the use of this particular nanoemulsion should not be recommended for 
human oral supplementation and further animal or in vitro studies should be done 
before clinical trials can be conducted.  
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